AUSTRIAEXPORT - Advantage Austria · 60 million euros annually for R&D in Austria. The latest...

austriantrade.org111/2005 1www.austriantrade.org1/2005 1www.austriantrade.org

No. 1 16 SPRING 2006 EDITED BY THE AUSTRIAN FEDERAL ECONOMIC CHAMBER, AUSTRIAN TRADE

AUSTRIANTRADE.ORG

AUSTRIAEXPORT

Biotech & more

austriantrade.org2 116/2006

3 EDITORIAL

4 ENORMOUS POTENTIAL FOR INNOVATIONS

6 AUSTRIA: A PROFITABLE LOCATION

8 BIOTECH MADE IN AUSTRIA

16 AUSTRIAN COMPANIES FOR PHARMACEUTICALS

21 AUSTRIAN COMPANIES FOR DIAGNOSTICS

23 AUSTRIAN COMPANIES FOR RESEARCH AND DEVELOPMENT

33 AUSTRIAN COMPANIES FOR BIOPROCESSING

35 SUPPLIERS

38 LISTING

41 INDEX

42 AUSTRIAN TRADE COMMISSIONS ABROAD

Biotech & more

Published: according to § 25 Law governing Media:Editor: Austrian Federal Economic Chamber, AUSTRIAN TRADE, A-1045Vienna, Wiedner Hauptstraße 63, T. +43/590 900-4822 • Publishing house:New Business Verlag GmbH, A-1060 Vienna, Magdalenenstraße 33, T. +43/1/2351366-0, F. +43/1/2351366-999 • Concept, editorial and pro-duction: PG The Corporate Publishing Group GmbH (CPG) • Chief coordina-tor: Oliver Olbrich (ext. 666) • Marketing editor: Lorin Polak (ext. 300) •Senior editor: Paul Christian Jezek (ext. 400) • Editors: Beyana Maghakian([email protected]) and Martin Spatz ([email protected]), both AustriaWirtschaftsservice GMBH, LISA • Promotions editor: Gudrun Just • Graphicconcept: Gerald Fröhlich (CPG) • Coordinating manager: Gesa Weitzenböck(+43/1/4054640-763) • Cover photo: Archiv AWO • Proofreading: SteveWilder • Print: AMG MediengmbH, A-1140 Vienna

AUSTRIAEXPORT

© A

rchi

v AW

O

AUSTRIAEXPORT

austriantrade.org116/2006 3

In the 21st century, biotechnology will be one of the mostimportant technologies of all, as it exercises an enormousamount of influence on broad sections of society and

offers solutions for a wide range of applications. Through the development of innovative medical pro-

ducts, therapies and diagnostic means, it also directly affectsthe making of health policy in general. Thanks to newopportunities relating to biotechnology in the field of foodand nutrition, it also influences general prosperity and qua-lity of life considerably, in addition to making importantcontributions toward the creation of an ecological society.

The biotech sector in Austria now encompasses more than10,000 employees, the majority in the field of human medi-cine, and it has a turnover of two billion euros per year. Thegeneral attitude toward "red” biotechnology and productscreated with the aid of medical research is extremely positi-ve. Attitudes are also improving toward "grey” biotechnolo-gy, which deals with the environment. Applications in indus-trial production processes (e.g. food additives such as citricacid, which is also used for decalcification; detergents; enzy-mes, e.g. for blood and grass stains; thickeners, such as xan-than gum; bioplastics; and pharmaceutical products andintermediates) represent Austrian activities in the field of"white biotechnology.” Biofuels (biodiesel, ethanol) areanother prospective field being currently developed. Theacceptance of gentle "green” plant biotechnology is stillbeing worked on.

In contrast to other groundbreaking technologies, prac-tical applications are found over the long term. Lead timesbetween idea and concrete effect sometimes amount toseveral years and can result in considerable expense, one

good example being the research and commercialisation ofnew medicines. While biotechnology was understood as themanufacture of genetically engineered agents in medicine afew years ago, the field now includes clinical tests, practicalapplications, accompanying diagnostics, medical technologyand even sales of essential biotechnological components.

For this reason, the opportunities with regard to deve-lopment and added value in the biosciences in Austria havenot yet been fully exploited, and they go beyond theborders separating disciplines. Real progress is normallyachieved through a transdisciplinary approach: networkingof specialised knowledge from the fields of biology, micro-biology, molecular biology, chemistry, and engineering andmaterial sciences is decisive for a great many solutions. Atpresent, technological progress in the relevant disciplinestakes place in parallel within separate methodological sys-tems. In other words, lateral communication among variousareas is decisive for innovation.

For the purpose of realising this potential in Austria,expanded networking activities, intensified interdisciplinaryand cross-sector research, and "translational” research aswell are all being encouraged. In addition to its direct workforce requirements, biotechnology generates and ensuresadditional jobs in related fields, especially the chemical andpharmaceutical industries. On the other hand, the merenumber of jobs is less important than the fact that theyrequire a high level of qualification and are accompanied byconsiderable economic value. The great significance bio-science has for pharmaceutical research and developmentmeans that biotechnology and the pharmaceuticals industrywill increasingly cooperate in equal partnerships. ❚

Paul Christian JezekSenior Editor

Biotechnology and Life SciencesKey Technologies in Austria

AUSTRIAEXPORT


Foreign companies and investors are interested in thegems in Austria’s biotech crown, one good examplebeing the 7.5 million dollars of financing provided to

Vienna’s Fibrex Medical Research & Development GmbH byGlobal Life Science Ventures, Atlas Venture, EMBL Venturesand Mulligan BioCapital AG.

In addition to flows of international capital, the acquisi-tion of domestic cancer-research company igeneon byAphton of the USA is also typical of the current activity.

Biotechnology firms located in Austria spend up to one-half billion euros on research each year. At present, vaccinesand therapeutic proteins, antibiotics and antiinfectives,medicines to treat cancer, non-steroid medications for neu-rodermatitis, DNA chips, "recombinant” allergenics, virusand prion activation, gene-transport systems and biochipsfor diagnostic purposes are being studied, with some pro-ducts already on the market.

Baxter AG, one of the country’s largest and fastest-gro-wing biotech companies, develops and manufactures medici-nes, in particular vaccines and therapeutic proteins.

Boehringer-Ingelheim Austria, located in Vienna, is thecentre of oncological research and development, at the sametime representing one of the two centres for biopharmaceu-tical production, in the international Boehringer-IngelheimGroup. Two block busters currently being marketed are: theactive ingredients Interferon gamma and tumour necrosisfactor alpha. Apart from the investments being made in newinfrastructure, Boehringer-Ingelheim outlays approximately60 million euros annually for R&D in Austria. The latestinnovation is a new kind of biofermenter for high cell-densi-ty fermentation of bacteria and yeasts.

And there’s more: Boehringer also runs the ResearchInstitute for Molecular Pathology (IMP), which was foundedin 1988. The most important institute in Austria that workswith molecular biology performs research on a variety ofsubjects, such as the development of cancer cells, and it hasearned an excellent reputation among international expertsin the field. Its neighbour, the Institute of MolecularBiotechnology (IMBA), is operated in close cooperation, andthe Gregor Mendel Institute for Molecular Plant Biology

First-rate research is performedat Boehringer-Ingelheim Austria.

Enormous potential for innovationsAustrian biotech companies can look back on an outstanding long tradition and at present make upa dynamically growing scene with such well-known members as Austrianova, igeneon, Intercell,Oridis and Sanochemia.

© B

oehr

inge

r-Ing

elhe

im A

ustri

a

AUSTRIAEXPORT


(GMI) is located in the same building. These two institutes,which belong to the Austrian Academy of Sciences performbasic research.

Sandoz GmbH (formerly Biochemie GmbH and a memberof the Novartis Group), with development and manufactu-ring operations in Kundl and Schaftenau, has 2,600 employ-ees and is the leading company for pharmaceuticals andgenerics in Austria. No less than 98% of its sales are madethrough exports to more than 120 countries. Enzymes, hor-mones and therapeutic proteins are manufactured in Kundl.

On January 31, 2006, Nabriva Therapeutics ForschungsGmbH, a biotechnology firm which focuses on antibiotics,opened its doors. This company is a spin-off of Vienna’sAntibiotic Research Institute (ABRI), part of the researchdepartment of Sandoz GmbH, Kundl.

Nabriva concentrates on developing antibiotics for hospi-tal-acquired infections and has an extremely solid pipeline ofantibacterial active agents. At present, three projects are at anadvanced preclinical stage, and one product will soon be inclinical phase 1.

The Campus Vienna Biocenter (VBC) is the product of asmoothly functioning symbiosis of the private sector andboth university and non-university research institutes.

The Intercell company, founded in 1998 and now listedon the stock exchange, is located at the Campus ViennaBiocenter. Vaccines used to treat diseases such as tuberculo-sis are developed here. Late in 2005, its partner Merck & Co.,Inc. provided 833,000 euros in recognition of "significantprogress.” The international market launch of a new vaccineagainst Japanese encephalitis is planned for 2007, and late in2005, Pelias AG was established as part of a major partners-hip of Intercell and Parteurop, a renowned consultancy in thefield of life sciences. Thanks to financial support provided bypartners around the world and the licensed projects ofChiron and Intercell, Pelias intends to develop new kinds ofvaccines and treatments based on antibodies. Its most impor-tant product is a vaccine against pseudomonas infections,and this medication’s effectiveness has been proven in initi-al clinical studies.

Another success at the Biocenter is VBC-GenomicsBioscience Research GmbH, which turns patented biochipexpertise into marketable products for diagnosing allergies inconnection with hormone-replacement therapy. Biomay AGhas entered into long-term collaboration with leading allergyresearchers at the medical universities of Vienna and Salzburgto develop new strategies for diagnosing and treating aller-gies, especially with "recombinant” allergens, i.e. those whichhave been produced through genetic engineering.

Hämosan develops methods relating to the activation ofviruses and prions in addition to tests and microbiologicalexaminations for veterinary medicine and the production ofhypericin.

The Novartis Institutes for BioMedical Research Austria,Vienna (NIBR) has been one of the most important centres inAustria for pharmaceutical research since 1970; at present, asa centre of excellence for dermatology, it performs researchon innovative treatments for inflammatory skin conditions(including neurodermatitis) and related allergies and immu-nodeficiencies for the Novartis group.

Igeneon – a Novartis spin-off created as one of Austria’sfirst biotechnology companies to work on cancer-immunitytreatment – develops vaccines designed to prevent or delaythe formation of metastases.

Austrianova, located at Vienna’s University of VeterinaryMedicine, is an international pioneer in the research, deve-lopment and use of viral gene-transport systems. A methodfor treating pancreatic cancer is the first and only in Austriato be registered as an "orphan medicinal product” by theEuropean Medicines Agency (EMEA). Late in 2005,Austrianova received credit guarantees totalling 3.5 millioneuros from the Austria Wirtschaftsservice bank to begin massproduction of NovaCaps, capsules containing geneticallymodified living cells which could be on the market by 2008.

Lambda GmbH of Upper Austria develops and manufac-tures biochips for diagnostic applications in addition to wor-king with bioanalysis and various kinds of DNA analysis. Thecompany also provides DNA sequencing and validation oftest methods in the form of commissioned research.

In close cooperation with Graz’s Technical University,Molekulare Biotechnologie GmbH offers technologicalexpertise relating to genetically engineered production ofenzymes with the Pichia pastoris fungus system.

Also noteworthy are biotechnological products, which aresold primarily for the manufacture of nutritional supple-ments. For example, Austria’s Jungbunzlauer is one of theworld’s most important producers of citric acid. Another itemmade for the food industry is the thickener xanthan gum.

The fact that agricultural biotechnology in Austria has todeal with difficult terrain is reflected by the number andnature of the country’s companies. Solely Maize Techno-logies International concentrates on crops.

Numerous other firms develop projects in the field of bio-technology, and they now occupy a firm position in the sec-tor. Included are C4 Holding, Fischer BiotechnologyConsulting and HL Bioscience. Some other newly foundedcompanies are Greenhills Biotechnology, Onepharm, Eucodisand Biodevelops.

In 2001, Austria’s biotech firms joined to form AustrianBiotech Industry (ABI), which is part of the Association of theAustrian Chemical Industry (FCIO). Both established compa-nies and biotechnology start-ups, most of which are active inbiopharma, comprise its membership. The ABI maintainsclose connections to European and international biotechno-logy networks. http://www.biotechindustry.at ❚

© In

terc

ell

AUSTRIAEXPORT


Austria’s geographical location provides ideal access tothe emerging markets of Central and Eastern Europe,which amount to almost 450 million people.

Vienna’s Schwechat Airport offers the highest number ofdirect flights into the new EU member states, and excellentmotorway and railway systems have been established.

Furthermore, the Danube links Austria with Slovakia,Hungary, Croatia, Serbia and Montenegro, Romania,Bulgaria, Moldova and Ukraine. In contrast to WesternEurope’s saturated markets, the nations of Eastern Europeoffer enormous opportunities, with up to 6% growth fore-cast in the coming years. The unanimous opinion of econo-mic experts is that Austria will benefit more than any otherEU member from the most recent enlargement, thanks to itslongstanding commercial ties to new member states. Mostimportant of all, however, is Austrian service providers’

extensive knowledge of Eastern Europe: for example, banks,management consultants and tax advisors have establishedwide-ranging contacts and gained a profound understandingof East-West business, knowing exactly "who, how and withwhom”. Leading companies from across the business spec-trum are choosing Austria as their support base for Centraland Eastern Europe: for example, global companies such asBoehringer, BASF, Bayer, Baxter, Beiersdorf, Siemens,Henkel, Degussa-Hüls and Eli Lilly have already establishedtheir Eastern European headquarters in Vienna.

There is much to learn about Austria as a business loca-tion. General information and support can be obtained fromthe Austrian Business Agency (www.aba.gv.at).

Low taxes

The reduction of the corporate income tax rate to 25% in2005 elevated Austria to a top position among Europe’smost business-friendly nations. Among the EU-15, onlyIreland offers more favourable tax provisions.

However, Austria also makes a strong showing in compa-rison to the new EU member states that are attracting inves-tors through major tax reductions. According to calculationsdone by the Vienna Institute for Advanced Studies, Austria’stax reform will reduce the effective corporate tax rate evenfurther, to 22%. This advantage is attributable to numerouswrite-offs, including a research premium of 8%. Researchand training exemptions, deductions for losses and the car-ryover of silent reserves are also resulting in significantreductions. Companies will benefit from the group taxationrelief: under the new provisions, the profits and losses ofdomestic group members are offset along with the losses offoreign subsidiaries, which reduces the basis for calculationof the corporate tax.

Up to 35% of research expenditures are excludable if app-lied to the development or improvement of inventions withmacroeconomic value. Investments in the form of silentpartnerships enjoy tax advantages under Austrian law andalso play an important indirect role in subsidising and finan-cing commercial research and development. Taken together,these provisions make Austria’s tax system the most attracti-ve in Europe with regard to research and development.

Investing in biotech

Outstanding research facilities and the presence of interna-tional pharmaceutical companies provide the framework forAustria’s thriving biotechnology scene. Support and assis-

Austria: a profitable locationThe ideal hub for Central and Eastern Europe: Austria’s attractive business environment offers politi-cal and social stability, close connections to the growth markets of Eastern Europe, superb educationand training for Austria’s workforce and a number of competitive tax advantages for companiesoperating in Austria.

Martin Spatz

Austria has anenormous amount ofpotential in the life-

sciences sector.

© W

WFF

AUSTRIAEXPORT


tance is provided to biotech companies primarily by thefederal Life Science Austria (LISA) programme and regionalinitiatives. LISA draws on many years of experience in thelife sciences to put this expertise at the disposal of potentialnew businesses. It provides help in drawing up businessplans and conducting market research and analysis. Adviceon patent law, assistance in identifying joint-venture part-ners and financiers, and a suitable infrastructure are alsomade available. LISA is administrated by the AustriaWirtschaftsservice (aws, www.awsg.at) federal bank onbehalf of the Federal Ministry of Economics and Labour.

In accordance with its corporate motto of "providingfinancing from establishment to flotation”, pre-formationfunding is available on favourable terms to allow for prepa-ration of a technical proof of principle (pre-seed financing).Mezzanine loans enable start-ups of young biotech compa-nies with an established technological foundation and highgrowth potential (seed financing). Both forms of financingare intended to help bridge the interval between start-upand the availability of risk capital.

Venture-capital investments can then be backed byAustrian guarantees: as companies mature, aws providesloans at competitive rates and growth financing in the formof guarantees for business investments. Investors inAustrian biotech companies include Atlas Venture, GlobalLife Science Ventures (GLSV), EMBL Ventures, MulliganBioCapital and TVM Life Science Ventures.

In addition, silent investments are very popular inAustria’s biotech scene due to special tax reductions. ❚

29 mil. euros: Intercell AG, Vienna, January 2001Global Life Sciences Ventures, Apax Partners, Nomura, TVM, NIB Capital, Star Ventures

30 mil. euros: Igeneon AG, Vienna, August 20013i, Novartis Venture Fund, DVC, DB-Investor, Dresdner Bank, CBG, Commerz Beteiligungsgesellschaft,Capexit, Horizonte

27 mil. euros: Intercell AG, Vienna, July 2003Apax, Nomura, TVM, GO Equity, Sal. Oppenheim, Alpinvest

27 mil. euros: Igeneon AG, Vienna, February 2004Burrill & Co, 3i, DVC, Novartis Venture Fund, Capexit, gamma capital partners, Horizonte, Invest AG

11 mil. euros: Biovertis AG, Vienna, September 2004TVM, Kapital & Wert

7.5 mil. euros: Fibrex Medical Inc., Vienna, March 2005Global Life Science Ventures, Atlas Venture, EMBL Ventures, Mulligan BioCapital AG

10 mil. euros: Biovertis AG, Vienna, December 2005TVM, Life Sciences Partners

42 mil. euros: Nabriva Therapeutics Forschungs GmbH,February 2006Nomura Phase4 Ventures, Wellcome Trust, HBM Partners,Global Life Science Ventures, Novartis Venture Fund

Largest VC Funding Rounds in Austria

The biotech sector in Austria now encompasses more than 10,000 employees, the majority in the field of human medicine,

and it has turnover of two billion euros per year.

© W

WFF

AUSTRIAEXPORT


Biotech made in AustriaIn the past decade Austria has proven itself to be an excellent location for research and developmentin the life sciences. A welcoming business environment, a prime location at the heart of Europe andits high quality of life all contribute to leveraging biotech growth in the country.

Beyana Maghakian

Austria is not only famous for musicians such asWolfgang Amadeus Mozart, whose 250th birthday isbeing celebrated in the year 2006; the field of medici-

ne has always possessed great significance here. When lookingback at the country’s history, many important contributions togroundbreaking progress in the life sciences stand out.

For centuries, the persistent innovative spirit of Austrianscientists has led to numerous discoveries which representmilestones in medicine, biology, chemistry and other scien-tific fields. In 1847, Ignaz Semmelweis for the first timeintroduced antiseptic measures for the prevention of child-bed fever. Toward the end of the 19th century, TheodorEscherich discovered the most important bacterium used inbiotechnology, Escherichia coli. And in 1901, KarlLandsteiner identified the blood groups, which earned himthe Nobel Prize.

Today’s focus: medicine

Modern Austria has successfully managed to maintain itsstrong medical tradition, and pharmaceutical giants such asSandoz Baxter, Boehringer Ingelheim and Novartis operateresearch and production facilities here, and as a result, bio-pharmaceuticals and bioprocessing are priority areas.Companies like Eli Lilly and Roche are important researchcontractor for the academic community in Austria. With theaim of satisfying the daily needs of hospitals and medicalpractitioners, a number of small and medium-sized compa-nies develop diagnostic tools, innovative services and noveltreatments.

In contrast to the concentration in red biotechnology, theplant and environmental sector can be described as rathersmall. In total, the country hosts about 150 small and

© C

PG/G

F©

CPG

/GF

Life Scienes in Austria

Tyrol3 universities36 primary companies with R&Dstrong focus in medical technology &informatics, drug development, bio-analytics & cell therapy

Vienna5 universities~ 100 primary companies with R&Dstrong focus in medical biotechnology,drug development, diagnostics andprocess development

Styria4 universities19 primary companies with R&Dstrong focus in medical technology,pharmaceutical processengineering & health management

R&D intensive primary companies

AUSTRIAEXPORT


medium-sized enterprises in the field of life sciences. Manyof these companies were founded as spin-offs by researchersfrom one of Austria’s 15 universities which engage in rele-vant activities, and these companies continue to benefitfrom their excellent academic connections.

Biotech products increase in importance

Despite being an infant industry just 30 years old, the glo-bal biotechnology sector can look back on an impressiverecord of success. In 2004, Ernst & Young counted over4,400 biotechnology companies worldwide with combinedrevenues of 54.6 billion US dollars. That means an increaseof 17% compared to 2003. Today, biotech products alreadyaccount for some 20% of the total pharmaceuticals market,and the proportion is expected to double by 2010.

Local specialities for a global discipline

The majority of Austrian biotech activities are concentratedin the Vienna Region, Tyrol and Styria. Numerous successstories have already been written there, and these locationsare still the places to look for vibrant activity. Recently,Upper Austria and Lower Austria have also turned theirattention to biotechnology.

Austria’s number one: the Vienna Region

After Berlin, Vienna is the second largest university city inthe German-speaking world. There are more than 120,000students currently studying and researching at its nine uni-versities, and all the life sciences are covered at five of them.

Nevertheless, the medical field clearly dominates, withcancer research, immunology and dermatology being themost outstanding areas. Together with excellent non-univer-sity research institutes such as the Novartis Institutes forBioMedical Research (NIBR) and Boehringer Ingelheim’sResearch Institute of Molecular Pathology (IMP), Vienna’suniversities provide a perfect environment for high-techcompanies.

There are a variety of excellent hospitals, and Vienna’sGeneral Hospital is one of the largest in Europe.

Multinational enterprises such as Baxter, BoehringerIngelheim, Novartis and top-ranking biotech and medtechcompanies as well are taking advantage of this environment.

Since 1998, there have been approximately around 50biotech start-ups, the majority focusing on red biotechno-logy. Together with the big players, these research-orientedenterprises employ about 6,500 people.

The successful flotation of Vienna-based Intercell inspring 2005 marks the beginning of a new era for bioindus-tries in Austria. The first public-sector company in this field,it develops innovative "smart vaccines” and continues astrong Austrian tradition of immunological expertise. Otherstart-ups have already managed to attract considerableamounts of risk capital, the most recent examples areNabriva focusing on novel antibiotics, Fibrex, whichspecialises in the treatment of reperfusion damage, andBiovertis. The latter company, which develops innovative

antibiotics, acquired Morphochem in 2005 to strengthen itsproduct pipeline. Austrianova has been granted orphandrug status by European Medicines Agency for its medica-tion designed to treat pancreatic cancer. Life Optics is todaythe world’s leading manufacturer of high-technology head-mounted vision systems for surgeons. And TissueGnosticshas developed an innovative system for analysing whole cellgroups and tissue samples which will be used in routine dia-gnostics.

Strong support is provided by federal and regional autho-rities. For example, Life Science Austria Vienna Region(www.lisavr.at) was founded as a central consultancy andcoordination centre for researchers and entrepreneurs.

LISA VR channels the various kinds of support made avai-lable by its co-initiators, i.e. Austria Wirtschaftsservice(www.awsg.at) and Vienna’s Center for Innovation andTechnology (www.zit.co.at), and offers professional assistan-ce and financing for start-ups.

Working in a holiday region: biotech in the Tyrol

Tyrol is known throughout the world as an excellent placefor a holiday. But in addition to its beautiful landscape, it isalso Austria’s second most important region for biotechno-logy, with some 3,000 people employed at 36 companies inthe life sciences. A total of 450 jobs have been created overthe past three years, and another 2,300 researchers are wor-king at Tyrol’s universities, including the prestigiousLeopold-Franzens University in Innsbruck, the InnsbruckMedical University and the newly founded privateUniversity for Health Sciences, Medical Informatics and

Applications of biotechnological knowledgewill in the near future dominate most areasof daily life.

© W

WFF

AUSTRIAEXPORT


Technology. The research performed in the fields of cellengineering, implant and implantation technology, medicaldevice, health and bioinformatics, bioanalytics and drugdelivery enjoys international renown.

Tyrolean life-science companies benefit from academicknow-how. For example, the AlcaSynn Pharmaceuticalscompany develops opioid receptor blockers for use in paintherapy. Thiomatrix utilizes thiolated polymer systems formucosal delivery of biomolecules such as polypeptides, andInnovacell works on new cell-therapy processes to replacedamaged muscle tissue.

The health informatics company Icoserve designed anadvanced image-management software solution for hospitals.

Over the past few years, about 50,000 square metres of lab and office space have been provided by publicauthorities.

The Tyrolean Future Foundation (www.zukunftsstif-tung.at) works to promote and develop the life sciences inthe region. Part of this organisation is the CompetenceCentre Medicine Tirol, where 111 researchers and entrepre-neurs are currently collaborating on a total of 19 projects.

From the very beginning, the Tyrolean Future Foundationhas also supported the Center for Academic Spin-offs Tyrol,Health Information Technology Tirol and the AustrianCenter Of Biopharmaceutical Technologies.

Healthcare technology in Styria: medical devices, whitebiotechnology and regenerative medicine

In Styria, the biotech scene is small but very dynamic.Two Graz-based companies, Oridis and ProtAffin, won Bestof Biotech’s Central European business plan award for thelife sciences two years in a row. Oridis, founded by Graz’sMedical University, concentrates on identifying moleculartargets for the treatment of diseases. ProtAffin, a Karl-Franzens University spin-off, develops genetically modifiedproteins for treating inflammatory illnesses. Transgenic ani-mal models employed in the study of neurodegenerativediseases is the speciality of JSW Research, also based inGraz. Graz is also known as the home of the Kplus ResearchCenter for Applied Biocatalysis.

White biotechnology and upscaling technologies arerapidly growing in Styria. Companies such as VTUEngineering Ltd., Lactosan Ltd. and Zeta Holding are majorplayers in the region.

Total healthcare solutions, including testing facilities, aremade available at the Center For Medical Research, wheretheir partners perform clinical trials (phases 1-3). The lifesciences in Styria also enjoy valuable support fromHuman.technology Styria (www.humantechnology.at). ❚

In Austria, a noteworthy biotechnology scene whichenjoys international recognition is already in existence.

The level of education in the domestic biotechnology sector is excellent compared

to other countries.

© H

ITT

© K

MT

AUSTRIAEXPORT

Life Sciences in Austria

Competence within the ClusterNetworked for Success

The cluster human.technology.styria, founded in the summerof 2004, combines research and economy in the fields of medi-cine, biotechnology, process technology and engineering inthe southern region of Austria.The enormous potential of the network results from its uniquedensity of competence.

Political Commitmentshuman. technology. styria is actively looking for cooperationand synergies. Currently, we cooperate with Austrian institu-tions and companies as well as institutions in the South-Easternmarkets and with selected international partners. To emphasizethe importance of this initiative, the cluster has been supportedby the Federal Ministry of Economics and Labour and the Sty-rian Business Promotion Agency (SFG) right from the beginning.

Ideal Infrastructure within a short DistanceBased on the potential offered by five universities, numerous pri-vate-public research organisations, two polytechnics and appro-ximately 120 companies within a short distance, the cluster rein-forces the cooperation between science and economy to create anarea of competence in the field of human technology. All mem-bers of the cluster are identified by the "member of” – Logo.

Our Goals:❚ Establishment of Styria as an internationally competitive site

for human technology

❚ Increase the number of companies with international presence❚ Increase the number of start-ups and spin-offs❚ Enhancement of competitiveness of existing companies

through enforced innovation

Our Vision:We are the preferred partner for international companies inthe area of medical device and regenerative medicine. Throughthe focus on "Integrated Health Care Solutions” we set a world-wide benchmark with our products and services.

Fields of Excellence:❚ Key Competences in Therapies

● Diabetes and Lipids● Intensive Care and Regenerative Medicine● Hearing Impairment

❚ Key Technologies● Process Engineering● Biocatalysis● Logistics

❚ Key Research Areas● Biometric Identification and Security● Cell Biology and Tissue Engineering● Bioinformatics, Biosensors and Telemedicine ● Material Sciences and Nanotechnology ❚

Human.technology Styria GmbH

A-8020 Graz, Reininghausstrasse 13

T. +43/316/587016-0 • F. +43/316/587016-16

[email protected] • www.human.technology.at

© C

roce

&W

ir

© D

AS

KU

NZF

OTO


12 116/2006

AUSTRIAEXPORT


Vienna Region as business location for Life SciencesInnovation meets Tradition

The Vienna Region has developed into an innovative centrefor the life sciences and it is a hub for Central and EasternEurope. Welcoming business environment, high quality of lifeand a prime location in the heart of Europe contribute toleveraging growth in the region.

Global Players in the Vienna Region A number of international companies are located in theVienna Region and maintain R&D departments as well as pro-duction facilities. ❚ Baxter: vaccines and blood plasma products❚ Boehringer Ingelheim Austria: biopharmaceuticals and

oncology; Research Institute of Molecular Pathology❚ Novartis including the Novartis Institute for BioMedical

Research Vienna ❚ Eli Lilly including its Vienna School of Clinical Research (VSCR)

Sustainable Growth of the Life Science CommunitySince the late 1990ies about 70 start-ups were founded inVienna. Together with universities, research institutes and thebig players on site they form a thriving Life Science commu-nity. The main focus of these companies is medical biotech-nology with the following priority areas:❚ Vaccines: Intercell (IPO at the Vienna Stock Exchange in

2005)❚ (Viral) cancer therapies: Austrianova; Greenhills Biotech-

nology

❚ Antibiotics: Biovertis, Nabriva, Pelias❚ Allergology and immunology: Biomay, Onepharm, Sciotec❚ Neuronal diseases: Affiris, Axon Neuroscience, Sanochemia

LISA VR — partner for scientists and companiesLife Science Austria Vienna Region (LISA VR) is the centralconsulting and coordination office for life sciences in theVienna Region and supports researchers and companies ontheir way into a successful economic future.❚ Assistance in starting a business and drawing up business plans❚ Funding of start-up activities e.g. proof of principle (proto-

typing) in cooperation with university business incubators❚ National and regional grants, subsidized loans and gua-

rantees ❚ Investor network❚ Training and networking: lectures, semi-

nars, business plan competi-tions

❚ Consultancy and net-work contacts for re-location projects ❚

Life Science Austria (LISA) Vienna Region

A-1010 Vienna, Ebendorferstraße 4

T. +43/1/4000-869 34 • F. +43/1/4000-7099

Sabine Ecker

[email protected] • www.lisavr.at

© B

OK

U

© P

ID/K

ullm

ann

© W

WFF

austriantrade.org

AUSTRIAEXPORT


Life Sciences -a technology of the future in Upper Austria!

Extensive know-how and potential among companies andresearch bodies Upper Austria is the leading federal province with regard tocommerce, industry and exports. Moreover, the role of bio-sciences and biotechnology in Upper Austria is to be massive-ly enlarged. This expansion is foreseen in the “InnovativeUpper Austria 2010” strategic programme.

Expansion in the education and research areas Education and research are of fundamental importance. Theestablishment and growth of courses in Medical Technology,Bio- and Environmental Technology and Bio-computing atUpper Austria’s Advanced Technical Colleges and the focus onbio-systems analysis at the Johannes Kepler University of Linztypify activities in these areas. Moreover, the Upper AustrianResearch (UAR) Centre for Biomedical Nanotechnology is al-ready involved in the federal research programme. While in theschools’ area, the integration of biotechnology into the curriculaof the Higher Technical Colleges for Chemical Plant Technologyand Foods Technology has generated considerable effects.

Close integration of business into the Life Sciences strategy For Upper Austria, four areas of application are of majorsignificance. ❚ Health. Upper Austria already provides ahome to market leaders such as GeneralElectrics (GE) and Greiner Bio One, as

well as a diversity of small and medium-sized companies fromthe sub-supply sector. The predominant factor in this regard ismedical technology, which is to be the object of expansion. ❚ Foods. Almost 200 companies are active in this economicsegment. The competent further development of foods tech-nology is an important factor in international competition.Keywords: functional food, proteins, lactose, enzymes, etc. ❚ Environmental technology. Around 100 enterprises are invol-ved in this rapidly expanding, internationally oriented sector.Biotechnology is supplying impulses for production innovationssuch as filter membranes in wastewater and waste treatment. ❚ Industry. Many of Austria’s leading industrial companies arebased in Upper Austria. Interesting areas of application in theLife Sciences field include process technology in the chemicalsand pharmaceuticals sectors, as well as in the paper industry.

Positive preconditions for commerce and industry. Companiesplanning to enter this sector find an excellent framework pro-vided by the Health and Foods Clusters and the EnvironmentalTechnology Network. Companies are assisted in their activities

and on the path to new technologies and inter-national markets. In summary, it can be statedthat the Life Sciences sector is booming, thepreconditions are positive and an entry intothe area will pay off. Upper Austria has agreat deal to offer and forming your ownopinion is more than worthwhile! ❚

OÖ- Technologie- und Marketinggesellschaft m.b.H.

A-4020 Linz, Hafenstraße 47–51

T. +43/732/79810-5005 • F. +43/732/79810-5008

Mag. Gerlinde Pöchhacker

[email protected] • www.ooe2010.at

© F

oto

stu

dio

Leu

tner

116/2006 13austriantrade.org

AUSTRIAEXPORT


Lower Austria – the home of high tech Innovative Strategies for Biotechnology

Technopols are combined technological and business centersspecifically established around recognized educational andresearch institutes. The Technopol Program of Lower Austria isa trendsetter in implementing the linkage of education/trai-ning, research and business. Lower Austria’s three Technopolsare already setting international standards: Technopol Krems inthe fields of biotech and regenerative medicine, TechnopolTulln in agro- and environmental biotechnology, TechnopolWiener Neustadt in surface technologies, microsystemsengeneering and medical engineering.

Technopol KremsThe city of Krems is pursuing an emphasis on biomedicine(tissue engineering, cellular therapies, extracorporeal bloodpurification) and healthcare services. Krems’ biomedical pro-duction processes and laboratory facilities meet the higheststandards both for Austria and for the EU. The Campus Krems with Danube University, IMC University ofApplied Sciences, and the Bio Science Park are the pillars ofTechnopol Krems that is setting new directions in biomedici-ne, pharmaceuticals and related health science sectors. Andthe best evidence that they are the right directions is thehost of international businesses strivingfor Krems.Internationally recognized compa-nies, like Ars Arthro Biotechnologie,Biotec Systems (Fresenius Medical

Care), Tissuemed Bioscience, Baxter Bioscience, Cell Danubeand Cells+Tissue Bank Austrian are neighbors in the techno-pol´s Bio Science park.

Technopol TullnThe Technopol Tulln focuses intensively on research and deve-lopment in the fields of agro- and environmental biotechno-logy. Biotechnical processes are developed in the areas ofplant and animal production, as well as environmental pro-tection. More than 200 highly specialized researchers are alre-ady active on-site. The Research Institute for Agro-Biotechnology (IFA Tulln), aDepartment of the University of Natural Resources and AppliedLife Sciences in Vienna, ranks among the leading research insti-tutes in Europe in the fields of biotechnology in animal andplant-production, bioanalytics, environmental biotechnologyand technology of natural materials. The University of AppliedSciences Wiener Neustadt in Tulln meets the demand for tech-

nical education in the field with its course ofstudy in “Biotechnical Processes”. Specia-

lisation in “natural materials technology”and “bioanalysis and monitoring” provi-des skilled scientists of global caliber. In the new Technology Center Tulln in-ternationally operating companies andstart-up’s, like Romer Labs®, Biopure,

55Pharma and Biomin are located. ❚

Technopol KremsMagnesitstraße 1

A-3500 KremsT. +43/2732/87470-230F. +43/2732/[email protected]

Technopol TullnTechnopark 1A-3430 Tulln

T. +43/2272/61375-10F. +43/2272/61375-44

[email protected]/technology

©zV

g ec

oplu

s

©N

ÖW

Hel

mut

Lac

king

er

©T

hule

Jug

14 116/2006austriantrade.org

AUSTRIAEXPORT


Tirol as a Location for Innovation Working where others spend their holidays

When you think of Tirol in Austria, you usually think of holi-days. Tirol fulfils all the wishes one can hope for as a holiday-maker in the Alpine region – 4,500 mountain peaks, hundredsof mountain lodges, umpteen million square metres of powdersnow, 3,500km of ski slopes and uncountable culinary delights.Nevertheless, when we speak of Tirol as a business location,there is one thing we should not forget: apart from tourism,Tirol has developed into a specialised high-tech location.

Tirol as a business location - mountainous habitat, healthybusinessThe Tirolean economy has a small structure. Thousands of smalland medium-sized companies operate in the various areas ofthe production, trade and service industries. The balancedrepresentation of industry guarantees healthy economicgrowth. Tirol leads the way in Austria with 1.9% growth lastyear. The gross value added in Tirol was approximately 16.9million euros. Next to small and medium-sized companies, thelarger domestic companies are also responsible for this. Theselarger companies impress worlwide with their know-how andhigh level of quality. The Tyrolean Life Science Research fieldsof cell engineering, implant- and implantation technology,medical device, health- and bioinformatics, bioanalyticsand drug delivery are internationallyestablished. The first industriallymanufactured Penicillin was made inthe small village of Kundl. Sandoz

maintains the largest production plant for generic medicamentsthere. Tirol’s unique location between the most importantEuropean economic areas has strongly shaped its economicdevelopment. The close proximity to the centres of populationconcentration in southern Germany (Munich 160km),Switzerland (Zurich 200km) and in northern Italy (Milan370km) predestine Tirol’s industries as specialised suppliers forlarger industries. Ideal transport connections make Tirol a hubfor the international exchange of goods and knowledge.

Tirolean FortitudeAlong with the exceptional position of its location, Tirol offersan economic area with further advantages for companies andemployees. Three universities, two colleges of higher educationand also technical schools ensure an excellent standard of edu-cation. Professional customer-orientated administration andpoliticians who act as direct contacts for economic matters gua-rantee flexible and uncomplicated bureaucratic procedures. In

combination with the high standard of living, these arenoticable advantages for a location. The

combination of qualified jobs and optimalleisure time possibilities, embedded inunique natural surroundings, attract topinternational executives to Tirol. Are you interested in further information?Then please don`t hesitate contacting us:

www.wirtschaftsstandort-tirol.at ❚

Tiroler Zukunftsstiftung

A-6020 Innsbruck, Kaiser-Jäger-Str. 4a

Contact: Dr. Harald Gohm

T. +43/512/57 6262 • F. +43/512/57 6262-10

[email protected] • www.zukunftsstiftung.at

©K

ompe

tenz

zent

rum

Med

izin

Tiro

l



AUSTRIAEXPORT

Pharmaceuticals

Agneter PharmaConsultingGmbH

Mariahilfer Strasse 71 / 15A-1060 Vienna

T. +43/1/5264244F. +43/1/5264366

Assoc.-Prof. Dr. Ernst Agneter ,MBA

[email protected]

PharmacoeconomicsAgneter PharmaConsulting GmbHis specialized in pricing and reim-bursement issues

As pricing and reimbursement questions aregaining importance and complexity, AgneterPharmaConsulting provides a full service inworking out strategies and preparing reim-bursement dossiers. All necessary docu-ments and negotiations for the Federation ofAustrian Social Security Institutions” (FASSI)are discussed with our clients and complete-ly done by us.

As chairman of the health economics andreimbursement committee of PHARMIG(Austrian Association of PharmaceuticalManufacturers), Dr. Agneter is working withseveral pharmaceutical companies.

As board member of "Life Sciences Vienna"2004 and chairman 2006, we are also focu-sing on Biotech start-ups. ❚

The founder of Agneter PharmaConsulting isa trained physician and specialized in phar-macology and toxicology. With the experien-ce at the Federal Institute of ExperimentalPharmacology (Ministry of Health), Dr.Agneter has dealt with preclinical and clinicalexpert reports for marketing authorization ofmedicinal products. After several years in theInstitute of Pharmacology at the University ofVienna and in the Department of ClinicalPharmacology at the General Hospital ofVienna Dr. Agneter was appointed Medicaland Marketing Director of an internationalpharmaceutical company in Austria.

In 2001 Agneter PharmaConsulting was foun-ded with the scopes of clinical expert reports,drug evaluation, pricing and reimbursementand strategic advice on clinical trails.

Research and DevelopmentPharmaceuticals

Dr. Ernst Agneter,Associate Professor,

MBA


AUSTRIAEXPORT

Pharmaceuticals

Boehringer IngelheimAustria GmbH

Dr. Boehringer-Gasse 5-11A-1121 Vienna

T. +43/1/80105/2141F. +43/1/80105/2440Dr. Monika Henninger

[email protected]

www.boehringer-ingelheim.at

Boehringer Ingelheim AustriaCommitted to Quality, TechnologyLeadership and Business ProcessExcellence

6,000 L, designed for high cell density pro-cesses requiring high oxygen demand andhigh heat removal. Products are highly puri-fied in modern recovery and purificationunits. Columns up to 1.6 meters and techni-ques such as adsorption, size exclusion,hydrophobic interaction or ion exchange areapplied. Explosion-proof areas allow stepsrequiring the use of organic solvents or largescale high performance liquid chromatogra-phy. The plants are approved multi-productfacilities registered with the Austrian HealthAuthorities, the EMEA, and the FDA.

Our Process Science Team guarantees a con-stant supply of innovative technologies the-reby improving process economy, robust-ness, product safety and quality. For ourhighly competitive and large scale plasmidDNA manufacturing technology which hasset the standard within the biopharma indus-try, Boehringer Ingelheim Austria was gran-ted the Frost & Sullivan Technology Leader-ship Award in 2005. Also in 2005, we recei-ved the Customer Value Award for provi-ding our international clients with the hig-hest quality customer manufacturing.

Value through Innovation. With our motiva-ted and highly qualified staff, we are dedica-ted to keeping our premier position in con-tract development and manufacture throughtechnology innovation, quality and regulato-ry compliance, as well as business processexcellence. ❚

Boehringer Ingelheim Austria is one of thebiggest pharmaceutical entities in Austria. Itis a 100 % affiliate of the Boehringer Ingel-heim group, one of the world’s 20 leadingpharmaceutical companies. As the "RegionalCentre Vienna”, the site is responsible for theAustrian market as well as for 28 countries inCentral and Eastern Europe.Besides pharmaceutical business and oncolo-gy research, Boehringer Ingelheim Austria isrecognised as one of the world’s premierContract Manufacturing Organisations. As a"one-stop-shop” we offer the complete rangeof services from cell banking to large scaleGMP manufacture of drug substance anddrug product. We focus on the developmentand manufacture of microbial derived bio-pharmaceuticals, such as proteins, plasmidDNA, antibody fragments and protein scaf-folds. In state-of-the-art GMP facilities wemanufacture products for clinical trials andmarket supply.

Large scale GMP manufactureAs proven by our history, Boehringer Ingel-heim Austria is committed to growth. Today,the site operates 3 plants for microbialfermentation with fermenter sizes up to

Plasmid DNA

Microbial Fermentation

Biopharmaceuticals

Contract Manufacturing


AUSTRIAEXPORT

Pharmaceuticals

Mycosafe DiagnosticsGmbH

Veterinaerplatz 1, CampusUniversity of Veterinary Medicine

ViennaA-1210 Vienna

T. +43/1/250 77-2150F. +43/1/250 77-2190

Professor Renate Rosengarten,DVM, PhD

[email protected]

The Mycoplasma SpecialistMycosafe is a leading expert for mycoplasma control ofbiopharmaceuticals

biologicals and biopharmaceuticals licensedby international agencies, such as the EMEAand the FDA, have been tested by Mycosafe. Mycosafe’s mycoplasma testing servicesinclude GMP-compliant testing methodsaccording to regulatory standards specifiedby the European Pharmacopoeia (PhEur) andthe US FDA, as well as less stringent DNAamplification methods (PCR). The PhEur- andFDA-specified testing procedures apply to allbiologicals and biopharmaceuticals producedin cell substrates and include a DNA stainingprocedure using indicator cell cultures todetect “non-cultivable” mycoplasmas, inaddition to broth and agar culture procedu-res. Mycosafe also offers PhEur and US FDAcompliant validation studies to qualify eachmycoplasma testing assay for the respectiveproduct to be tested. In addition, Mycosafeoffers its expertise in mycoplasma speciesidentification and strain characterisationusing molecular techniques, and also provi-des consultancy and training services in thearea of mycoplasmology.In cooperation with academic and industrialpartners, Mycosafe is developing and valida-ting new innovative DNA-based testing sys-tems for the detection and identification ofmycoplasmas. Following acceptance by theregulatory authorities, it is expected thatthese easy-to-handle new molecular techno-logies, which provide results within a fewhours, will be increasingly used as an alter-native or additional method to the currenttime-consuming standard procedures. ❚

Mycosafe was originally founded in Decem-ber 2003 by Professor Renate Rosengartenunder the name Mycoplasma Testing &Consulting GmbH as the first and only com-pany in Austria and one of the few in Europeoffering a wide range of mycoplasma testing,consultancy and research-related services forthe GMP-compliant quality control of celllines and cell culture-derived biologicals inresearch, biopharmaceutical processing andproduction. Located on the campus of theUniversity of Veterinary Medicine Viennaand having its roots in the Institute ofBacteriology, Mycology and Hygiene, a uni-versity institute which is internationallyrecognised for its research on mycoplasmas,Mycosafe is well-positioned to become amycoplasma testing service center and devel-oper of new mycoplasma testing assays ofthe future. Since December 2004, Mycosafe is operatingunder the new name Mycosafe DiagnosticsGmbH and is today considered as a leadingcontract service and research organisationwhich plays an important role in the successof its clients in research and biopharmaceuti-cal production by assuring the mycoplasmabiosafety of cell banks, in-process samples,lot-release samples and raw materials. Several

Mycoplasma-contaminated cell line

Mycoplasma Detection & Identification

Contract Research & Development

Mycoplasma Control of Biopharmaceuticals

Regulatory Testing (PhEur & FDA)


Dr. Atkins: Cancer can be reversed

AUSTRIAEXPORT

Pharmaceuticals

Nowicky PharmaMargaretenstraße 7

A-1040 ViennaT. +43/1/586 12 23F. +43/1/586 89 94

Dipl. Ing. Dr. Wassil [email protected]

www.ukrin.com

“149 scientists from 16 countries in 47 uni-versities and research institutes have carriedout detailed tests on UKRAIN® and publis-hed their results in more than 120 scientificpapers indicating the importance ofUKRAIN® for cancer therapy. Dr. Atkinsregards UKRAIN® as the single best antican-cer agent he has used to date. "Like chemo-theraphy, it kills cancer cells very well, but,unlike chemotheraphy, it spares normalcells, healthy tissue. If the medical commu-nity were willing to give it a try, UKRAIN®

could replace chemotheraphy in treatingalmost all cancers." - Robert C. ATKINS, M.D.

The Ukrainian Anti-Cancer Institute (UACI) isa non-profit organization dedicated to freeand independent scientific research onUKRAIN®. To the present day 16 countrieshave participated in the UACI research withmore than 150 scientists in 46 universitiesand research institutes. The results of UACIresearch are regularly presented on interna-tional congresses and published in scientificmagazines.

The exciting story about the development ofUKRAIN® is examined by the science journa-list Eleonore Thun-Hohenstein. Readingabout that, one wonders if this discovery issuppressed because it is against some phar-maceutical companies' interests.

(Interview with Dipl. Ing. Dr. Wassil Nowicky) ❚

UKRAIN® is a derivative of alkaloids fromthe plant greater celandine and the pharma-ceutical thiotepa and is used in the cancertherapy. Both of these substances are appro-ved as human drugs and are commonly usedin hospitals.In contrast to cytostatica, the inhibition ofcell division by UKRAIN® is confined totumour cells, while the cells of healthy tissueremain unaffected. Excellent tolerance toUKRAIN® therapy is a result of this fact. Thedrug is easy to use and the therapeutic dosehas no significant side effects.

The main advantage of UKRAIN® is that itselectively kills cancer cells and fortifies thebody's defences. UKRAIN® destroys cancercells through apoptosis without attackinghealthy cells,thereof results the excellenttolerance. Beside that, UKRAIN® does notcause any kind of damaging side effects.

UKRAIN® activates a whole series of highlyeffective immune system mechanisms andbrings about the encapsulation of tumoursthrough antiangiogenesis (the inhibition ofnew blood vessels formation at the tumoursite), thereby increasing operability.

Direct order: [email protected]

Anticancer drugPharmaceuticals

UKRAIN®

The powerful anticancer drug

”


AUSTRIAEXPORT

Pharmaceuticals

SANOCHEMIAPharmazeutika AG

Boltzmanngasse 11A-1091 Vienna

T. +43/1/3191456-0F. +43/1/3191456-344

Margarita [email protected]

SANOCHEMIA Pharmazeutika

The Specialty Pharma Company

An additional sphere of activity involves themanufacture and sale of radiological pro-ducts distributed through our SanochemiaDiagnostics subsidiaries. Sales offices havebeen established in Germany, Switzerland,the UK and USA.

Strategy – Our focus lies on those sections ofthe pharmaceutical value-added chain inwhich we have in the past amassed signifi-cant levels of expertise and experience. Thisencompasses developmental skills, regulato-ry procedures and the synthesis of complexAPIs and forms the key to a range of long-term competitive advantages. The majorityof our revenues are already generatedthrough product sales.

Profitable contract manufacturing orders,API synthesis and imaging diagnostic salesall contribute to steady revenue flows.Additional potential lies in pipeline develop-ments of new drugs for attractive segmentsof the pharmaceutical market. Our in-housedevelopment projects are financed throughoperational cash flows. ❚

Sanochemia has elected to concentrate onthe development and manufacture of inno-vative specialty pharmaceuticals in indica-tions with a high degree of therapeutic com-plexity such as neurodegeneration, pain andcancer. Our products target segments cha-racterised by both unmet medical need andinteresting revenue potential.

Profile – Our strength and expertise lies in theefficient management of complex pharmaceu-tical development projects from pre-clinicthrough to registration. We consciously avoidbroad-based and cost-intensive exploratoryresearch. Extensive in-house skills and resour-ces are supplemented by numerous top-levelscientific co-operations with contract researchorganisations, institutes and universities.

Sanochemia’s patented development of ste-reoselective synthesis processes for activepharmaceutical ingredients (API) forms acentral factor underpinning our growth. Thisin turn allows us to offer partners a widerange of services in the fields of contract syn-thesis and manufacturing.

Research and Development

Specialty Pharma Company

Pharmaceuticals

Diagnostics


Making the world’s food safer

AUSTRIAEXPORT

Diagnostics

Romer Labs DiagnosticGmbH,

TZT, Technopark 1A-3430 Tulln

T. +43/2272/615 3310-10M. +43 664 814 37 86F. +43 2272-61533-111

COO Gustav [email protected]

BiopureReferenzsubstanzen GmbH

Technopark 1A-3430 Tulln

T. +43/2272/615 33 20F. +43/2272/615 33 211Dr. Martin Freudenschuss

[email protected]

Quantas Analytics GmbHTechnopark 1A-3430 Tulln

T. +43/2272/615 33 30F. +43/2272/615 33 311

Dr. Hannes [email protected]

www.biopure.at

Biopure Referenzsubstanzen GmbHwww.biopure.at

The basis of good analytical methods is theavailability of appropriate reference materialof defined purity and concentration. How-ever, the purity of mycotoxin standards isoften uncertain. Founded in the year 2001,Biopure has developed world-leadership inthe production of highly purified mycotoxincalibrants. Today thousands of labs in all con-tinents benefit from the liquid and solid cali-brants supplied from Biopure.

Quantas Analytics GmbH

As a result of the cooperation with the IFATulln – (Institute for AgrobiotechnologyTulln) Quantas Analytics were foundedrecently in order to transfer research resultsinto a service for routine analysis. Because ofnew regulations, the testing of mycotoxinshas become very important also for remoteplaces, where no Labs can be established.Therefore samples need to be sent to a center of competence which takes care ofanalyzing. ❚

More then two decades of experience withmycotoxins and the close cooperation withrecognized international universities provi-des us access to information about occurren-ce, toxicological and health effects, influenceof food and feed processing and state of theart technologies for testing. We use our expe-rience and knowledge to help clients to setup a mycotoxin control system and to mana-ge the risk.

Romer Labs Diagnostic GmbHwww.romerlabs.com

Romer Labs offers innovative and highlyefficient solutions for Mycotoxin TestingLabs.❚ ELISA-test kits for Total Aflatoxin,

Deoxynivalenol, Zearalenon, Ochratoxin,Fumonisin, T-2

❚ Rapid test kits for Aflatoxin, DON – GIPSAapproved

❚ Clean up columns, Immunoaffinitycolumns for chromatographic methods

❚ Sampling devicesAs part of the Technology Center Tulln, a focusis set in R&D, to ensure continuously new pro-duct output, which meets market demands.

reference materials

Anayltical Lab service


Suppliers


AUSTRIAEXPORT

Diagnostics

vitateq biotechnologyGmbH

Innrain 66A-6020 Innsbruck

T. +43/512/504 25590F. +43/512/504 25599

CEO Prof. Hans Dieplinger, [email protected]

Vitateq Biotechnology LLC

A company dedicated to humanfertility

tory. Presently, there are no comparable pro-ducts available on the market.

Very recently, Vitateq has discovered that afa-min is also related to other diseases. Afaminexerts neuroprotective properties in neuronalcell culture models. These results indicate ahigh potential for diagnostic and therapeuticapplications of afamin not only in the fieldsof fertility and cancer, but also neuropro-tection.

Vitateq Biotechnology is a spin-off companyfrom the Medical University of Innsbruckwith international management. The com-pany’s knowledge-based technologies inclu-de proteomics and state-of-the-art molecularbiology techniques. Our product develop-ment is protected by several internationalpatents. Scientists at Vitateq have more than15 years of extensive research experience onafamin, as documented by several publica-tions in highly renowned international bio-medical journals, such as:

Characterization of the vitamin E-bindingproperties of human plasma afamin (2002)Voegele AF, Jerkovic L, Wellenzohn B, EllerP, Kronenberg F, Liedl KR, Dieplinger H.Biochemistry 41:14532-14538.Afamin is a novel human vitamin E-bindingglycoprotein: characterization and in vitroexpression (2005) Jerkovic L, Voegele AF,Chwatal S, Kronenberg F, Radcliffe CM et al.J Proteome Res 4:889-899. ❚

Vitateq focuses on the identification and in-depth characterization of proteins related tohuman fertility. Vitateq was the first to dis-cover that afamin, a human serum transportprotein for vitamin E, is a major player in thedevelopment of reproductive tract tumors,infertility and neurodegenerative diseases.

Vitateq has established an ELISA kit forquantifying afamin in human serum as anovel diagnostic tool for early, improved andmore specific detection of cancers occurringin human reproductive tissues. This ELISAkit is fully developed and has already beentested successfully in several human patientgroups. Vitateq’s cancer diagnostic ELISA isready for entering a large-scale clinical trial.

Furthermore, Vitateq is developing the world’sfirst IVF laboratory diagnostics for identify-ing human embryos with a high potential forsuccessful implantation in the uterus anddevelopment into a full-term baby. Our newdiagnostic test will be based on a variety ofsignificant and biologically relevant biomar-kers. Such a product has an extraordinarymarket potential because it is non-invasive,reliable and easy to use in a routine labora-

Suppliers

Testis, ovar & cervix cancer diagnostic


Infertility treatment


AUSTRIAEXPORT


Amynon Biotech GmbHInnrain 66/III

A-6020 InnsbruckT. +43/512/504 25767F. +43/512/504 258 52CEO Dr. Barbara Fitzky

[email protected]

Make it visibleTumour Diagnostics in Motion - To Be in the Know IncreasesQuality of Life

males and females per year - and the low sig-nificance of existing diagnostic approachesthere is a high market potential for simple,fast and safe diagnostic test procedures. Amynon’s PapTec® assays are based on anti-bodies that allow the highly specific detec-tion of the hr HPV-E7 oncoprotein in clinicalsamples (smears, liquid based cytology,tumour biopsies, body liquids and cell ly-sates). In contrast to existing approaches, thePapTec® does not detect HPV infections butgives a positive signal in the case of a tumourdevelopment caused by hr HPV.Amynon’s second product line consists ofsome assays for early diagnosis of age associ-ated dysfunctions in the skin and cardio vas-cular system.

PartnershipsAmynon Biotech GmbH follows an efficientstrategy to protect intellectual property andhas filed several patents. The rights for pro-duction and distribution are licensed to part-ners from the pharmaceutical industry. As ascience-based and market oriented companyAmynon is permanently interested in inter-national cooperations with diagnostic andpharmaceutical companies to further deve-lop and commercialize Amynon's products.

Due to its innovative approach, which isbased on the latest scientific results, the pro-ximity of the products to market demandand a strong patent position, Amynon mightbe an interesting partner. ❚

Amynon Biotech GmbH, founded 2002 inInnsbruck, Austria, is a biotechnology com-pany specialized in research and develop-ment. Core competence of the company is tostudy changes of gene expression andfunction in human tissues during cancerdevelopment and ageing, with the intentionto identify and validate new targets for earlydiagnosis of tumour-, age- and environment-induced diseases. Amynon develops diagnos-tic assays up to the prototype including‘proof of concept’ studies.

Amynon’s first line of products, the PapTec®

assays, are developed for the early diagnosisof HPV-induced tumour diseases, especiallycervical cancer and other anogenital cancers.The products are currently in preclinical trials. At present, cervical cancer screening is thelargest existing screening market in oncolo-gy. Worldwide, there are 470.000 new casesof cervical cancer each year causing morethan 230,000 deaths. Human papillomavirus (HPV) induced cervical cancer is themost common cancer beneath breast cancerin women and, if detected early, cervical can-cer is a fully preventable disease! Due to highHPV infection rate - more than 300 million

Make it visible - HPV-E7 oncoproteindetection in cervical smear.

DiagnosticsResearch and Development


AUSTRIAEXPORT


Apeiron BiologicsForschungs- und

Entwicklungs GmbHBrunner Strasse 59

A-1230 ViennaT. +43/1/865 65 77

F. +43/1/865 65 77-9280Dr. Hans Loibner, CEO

[email protected]

Apeiron BiologicsTranslation of biological discoveriesinto novel biopharmaceuticalproducts

enzyme for the therapy of this life-threate-ning lung failure. ACE2 is expected to beactive against ARDS irrespective of theunderlying disease.A second project of Apeiron relates to thebiologic role of Cbl-b, a key check-pointmolecule of the immune system. The enzymeCbl-b has been recognized as critical negativeregulator of autoimmunity. Modulation ofCbl-b activity may enable effective vaccina-tion strategies against weakly immunogenicantigens such as cancer, malaria, HIV-infec-tion, or alternatively may lead to novel thera-pies for autoimmune diseases. In a strategicpartnership Apeiron identifies and profilessubstances that interfere with Cbl-b activity.In a third project, Apeiron in a strategic alli-ance identifies compounds that modulate thebiologic action of DREAM, a key moleculefor the natural pain regulation by controllingthe expression of an endogenous opioid.Such compounds are expected to be power-ful analgesics, based on the induction of theproduction of an endogenous opioid.Initial funding of Apeiron Biologics was pro-vided by its founders as well as by supportinstitutions including "Austria Wirtschafts-service”(AWS), "Zentrum für Innovation undTechnologie” (ZIT) of Vienna, and the SixthResearch Framework Programme of theEuropean Union.Apeiron’s premises are located on the campusof the Novartis Research Institute Vienna,taking advantage of the impressive infrastruc-ture of a big pharmaceutical company. ❚

Apeiron Biologics GmbH is a biotechnologycompany located in Vienna, Austria. Its objec-tive is to develop novel and innovative drugsfor the treatment of diseases with a highdegree of unmet medical needs. The companywas founded by Josef Penninger, Director ofthe Institute of Molecular Biotechnology ofthe Austrian Academy of Sciences (IMBA), atop-level scientist with high internationalreputation. CEO is Hans Loibner, who hasmore than 25 years experience in PharmaR&D and has founded and successfully deve-loped an Austrian biotech company.Apeiron´s key project is the development ofa therapy for the Acute Respiratory DistressSyndrome (ARDS). ARDS affects at least onemillion individuals worldwide/year and hasa mortality rate up to 50%. Presently no drugis available to treat this life-threatening con-dition that is caused by a variety of diseasessuch as sepsis and pneumonias due to viralinfections (e.g. influenza, avian flu, SARS).ARDS may be the key complication in thecontext of the feared pandemic outbreak of anew influenza virus. There is now proof thatAngiotensin Converting Enzyme 2 (ACE2) isa central molecule for the development andprogression of ARDS. In consequence,Apeiron develops a recombinant form of this

Preclinical Models

Clinical Studies

Drug discovery



AUSTRIAEXPORT


CIS Clinical InvestigationSupport Pharmaforschung

Gesellschaft m.b.H.Kaiserstraße 43A-1070 Vienna

T. +43/1/523 40 15F. +43/1/523 40 15-99

Dr.med. Dr.phil. Gerhard [email protected]

www.cis-qa.com

CIS Société Anonyme, Place Rouppe 19, B-1000 Brussels,

Total Quality Consulting

Clinical research & development,quality assurance and regulatoryaffairs

CIS S.A. has performed audits in more than30 different European and non-Europeancountries such as e.g. Argentina, Austria,Australia, Belgium, Brazil, Canada, Denmark,France, Germany, India, Israel, Morocco, TheNetherlands, New Zeeland, Portugal, SouthAfrica, Spain, Sweden, Switzerland, Turkey,United Kingdom, United States, includingalso a large number of countries in EasternEurope, such as Belarus, Bulgaria, CzechRepublic, Croatia, Estonia, Hungary, Latvia,Lithuania, Poland, Romania, Russia, Slovakia,Slovenia, and Ukraine. CIS prepares compa-nies for inspections by health authorities.

CIS offers consulting and project manage-ment services, starting from the switch pre-clinical-to clinical development up to sub-mission for marketing authorisation. Thisincludes also "coaching" of projects or staff-training "on the job" in case of temporaryshortages of resources of the client. ❚

Quality is the key factor for success. Poor quality in R&D, from planning to theconduct and analysis/reporting, is the maincause why studies fail or need to be repea-ted, causing increased costs, delays, and therisk of having the marketing authorisation ofa product denied.

CIS considers quality assurance services notonly as an instrument to increase or main-tain quality as well as competition, but alsoto reduce costs.

CIS has provided consulting & quality assu-rance services to more than 20 pharmaceuti-cal companies including CROs. Most of themhave trusted CIS repeatedly with variouskind of projects, from early development tosubmission for Marketing Authorisation.

CIS has a broad experience in conductingaudits in all major areas of clinical research.

R&D Consulting

Marketing Authorisation Support

Quality Assurance / Q Management Services

Audits


AUSTRIAEXPORT


EUCODIS GmbHBrunner Straße 59

A-1235 ViennaT. +43/1/866 34 9240F. +43/1/866 34 449

CEO Wolfgang Schö[email protected] und offi-

[email protected]

Facts about EUCODISInnovations Made by Nature

EUCODIS is an independent private compa-ny and financed by governmental researchfunding, venture capital and an increasingstream of income by research collaborations.Beside its headquarter and main laboratoriesat Vienna, EUCODIS has a subsidiary at oneof the leading European research institutes,Necker Faculty of Medicine in Paris. EUCO-DIS staff size is about 25 co-workers. EUCO-DIS has a strong international network ofleading experts for its individual projectswhich ensure optimal project design andperformance of research and collaborativeprojects. In industrial enzymes EUCODIS ismember of the Competence Center forApplied Biocatalysis at Graz, Austria. Majorresearch collaborations with the NeckerFaculty of Medicine and leading institutes inEurope linked via a major grant from EUfocussing on human antibodies are in place.

Within shortest time EUCODIS coulddemonstrate the validity and power of itstechnologies and know-how by a number ofindustrial collaborations such as Sanofi-Aventis, Biocatalytics Inc, and PLIVA,Croatia. In addition to these collaborativeservice agreements, internal projects arefocussed on biopharmaceuticals (anti-inflam-mation and bone metabolism) and twoimportant enzyme classes. EUCODIS expectsto enter preclinical development in 2007 byits internal projects whereas first industrialenzyme products for licencing are availablein 2006. ❚

EUCODIS GmbH founded in 2004 at Vienna,Austria, is a biotechnology company success-fully generating novel products in the lifescience area by applying the two mostpowerful technologies mimicking naturalprocesses of evolution, in vivo recombina-tion and somatic hypermutation.

Technology Base of In Vivo Recombination Recombination of genes is normally limitedto very high DNA sequence homology. TheEUCODIS proprietary approach extendsthese natural limitations to recombination ofhighly diverged sequences and thus createsproteins with novel properties coded by therecombined gene sequence. EUCODIS hasset up proprietary tools which efficiently andquickly create highly diversified libraries.EUCODIS demonstrated the superiority of itstechnology in several projects: generation oflibraries with a high percentage of active pro-teins and broadest diversity – more needlesin a smaller haystack!

Technology Base of Somatic Hypermutation The EUCODIS approach mimics the affinitymaturation process by which mammalianorganisms generate high affinity antibodies.Iterative stimulation of a human B-cell lineallows the generation of specific, humanantibodies or novel biopharmaceuticals.

Human Antibodies

Fermentation Optimisation

Industrial Enzymes

Biopharmaceuticals


AUSTRIAEXPORT


Fibrex Medical Research &Development GmbH

Brunnerstraße 59A-1235 Vienna

T. +43/1/86634-9270F. +43/1/86634-9279Dr. Rainer Henning

[email protected]

Fibrex Medical FIBREX Medical is developing newdrugs for serious inflammatorydesease

damage of the heart muscle after experimen-tal myocardial infarction. Recently, FIBREX Medical has filed an IMPDfor the treatment of cardiac reperfusion inju-ry and has completed phase I clinical trials inQ4/2005. In parallel, research programs foradditional indications for FX06 will be con-ducted and suitable indications for clinicaldevelopment will be identified, with anemphasis on septic shock. New peptidesalready identified will be analysed with res-pect to their usefulness for autoimmunediseases. In Q2/2006, FIBREX Medical willbegin a phase IIa clinical trial of FX06 in car-diac reperfusion injury to achieve the proofof concept in man. In parallel, partneringdiscussions with a pharmaceutical partnerfor performance of phase III trials and com-mercialization will be started. Phase IIa trialsfor additional indications for FX06 will beinitiated in 2007. FIBREX Medical currently concentrates itsefforts on the preclinical and clinical deve-lopment of the products currently in its pipe-line. However, in-licensing of product candi-dates (late preclinical or early clinical) with astrategic fit will actively be pursued to com-plement the pipeline. Research activities forprofiling its product candidates will be donein close collaboration with the laboratoriesof the company´s scientific founders as wellas its scientific network.It is expected that FX06 will be out-licensedto a pharmaceutical company in the courseof clinical phase II. ❚

FIBREX Medical Inc. is a development stagebio-pharmaceutical company. Its operationalaffiliate Fibrex Medical Research & Deve-lopment GmbH was established in Vienna inFebruary 2001. Concurrently with the foun-dation of the U.S. holding company, FIBREXMedical has completed a US $10 millionSeries financing round in March 2005 co-ledby Atlas Venture and Global Life ScienceVentures (GLSV). The company aims to beco-me a leader in the development and com-mercialisation of pharmaceuticals targetingfundamental mechanisms of inflammation-based tissue injury. Using its automatedscreening technology, FIBREX Medical hasidentified several anti-inflammatory pepti-des. Inflammation-based tissue injury is wellknown as a major component in the patho-genesis of important diseases, such as myo-cardial infarction, septic and hemorrhagicshock, graft rejection or rheumatoid arthri-tis. The most advanced development productof FIBREX Medical – a peptide with the codeFX06 – is developed for the indication cardi-ac ischemia/reperfusion injury; it aims atmarkets with more than 5,000,000 potentialpatients per year in the developed world. Inanimal studies FX06 significantly reduced

FX06 reduces infarct in experimental models.

Anti-inflammatory peptides

Myocardial infarction

Pharmaceuticals



AUSTRIAEXPORT


Ionimed Analytik G.m.b.H.

Technikerstr. 21aA-6020 Innsbruck

T. +43/512/507-4810F. +43/512/507-9818

Dr. Armin [email protected]

Ionimed AnalytikOnline trace gas analysis for use inthe biotechnology and medicalindustries

avoids fragmentation, exact mathematicalmodels may be used to accurately quantifythe detected masses of compounds. Anotherbenefit of our products using H3O+ ions isthat the results of PTR-MS measurements arenot modified or falsified by high concentra-tions of water vapor in the gas samples to beanalyzed.

Compared to ordinary gas chromotography,our PTR-MS system provides the possibilityof online and real-time measurement, be-cause the instrument's response time is lessthan 100 ms. There is no need for anysample preparation before injection into thePTR-MS inlet.

For example, PTR-MS can be applied to thefollowing:❚ Process control in biotechnology by head

space monitoring of VOCs emanating fromfermentation

❚ Evaluate cell processes by characterizationof emitted VOCs

❚ Non-invasive diagnosis for the medicalindustry via sensitive detection of VOCsfrom exhaled breath that can be used asmarkers (e. g. for the prerecognition ofdisease)

In addition to offering a variety of instru-ments incorporating PTR-MS technology forsale, Ionimed Analytik offers instruments forhire as well as expert analysis by our team ofgas samples containing VOCs. ❚

Ionimed Analytik GmbH is a young spinoffcompany in Innsbruck, Austria with exper-tise in the detection and quantification of tracegases in air using proton-transfer-reactionmass spectrometry (PTR-MS), specifically forthe fields of biotechnology and medical re-search. High quality PTR-MS instruments forsatisfied customers from industry, universityand private research have been employed inthe food and fermentation control industriesas well as for process and environmentalmonitoring. The very low detection limit forvolatile organic compounds (VOCs), real-time measurements due to fast responsetimes, and continuous monitoring capabili-ties are the major advantages of our innova-tive PTR-MS system.

PTR-MS technology was developed by scien-tists at the Institute of Ion Physics at theLeopold-Franzens University in Innsbruck. Asoft (low fragmentation) ionization methodbased on proton transfer reactions fromH3O+ ions to all compounds with a higherproton affinity than water is used in ourdevice. This leads to our unique low detec-tion threshold for trace compounds in therange of a few pptv. Since our technique

Compact real-time VOC detector.

Trace Gas Analysis

VOC Quantification

Online Analytics

Process Monitoring


AUSTRIAEXPORT


JSW - ResearchForschungslabor GmbH

Rankengasse 28aA-8020 Graz

T. +43/316/765114 22F. +43/316/765114 4

Robert Wronski, PhD, [email protected]

JSW-ResearchAging with a Clear Mind

ding transgenic disease models. Dr.Windisch, CEO of JSW-Research: For theidentification and evaluation of compoundswe apply a broad spectrum of biochemical,cell biological and molecular biologicalmethods. Furthermore we are specialists inneuroscience and behavior and work withvarious animal models including transgenicmice. Dr. Windisch founded the company in1999 and gained profound knowledgeduring a 20 year career in drug research. Inthe preclinical field JSW-Research focuses onage related diseases of the central nervoussystem: Alzheimer’s disease, Parkinson’sdisease, vascular dementia but also cerebro-vascular disease mediated neurodegenera-tion. The clinical department of JSW-Research offers services in all clinical phasesand indications.

JSW-Research generates high quality researchon two levels: First the company performshighly standardised contract research for thepharmaceutical industry and for well renowninstitutions like Harvard University, MayoClincs and the University of Tel Aviv. 99% ofJSW’s customers come from abroad.Academia represents a significant proportionof the customers, since the Austrian enterpri-se is one of the technology leaders regardingpreclinical and clinical research. In a secondbranch JSW-Research performs proprietarydrug development programs. It is the primarygoal of the company to improve the quality oflife of patients and their relatives. ❚

Research focused on finding powerful treat-ment strategies for age related brain diseasesis the central purpose and responsibility ofJSW-Research.

The company is also dedicated to providingtop-level clinical research on a broader rangeof illnesses throughout all stages of therapydevelopment.

JSW-Research Ltd., Graz, Austria, offerscomprehensive research and consulting pro-grams for drug development concerningdisorders of the central nervous system.JSW-Research uses modern molecular biolo-gy techniques and has also designed a varie-ty of disease relevant cell and animal modelsfor characterizing drug effects. Interlacingmodular systems facilitate step-by-step analy-sis of candidate substances from basic invitro to complex in vivo assays, complemen-ted by a full range of histological, biochemi-cal and behavioral evaluation methods.

The Austrian contract research and drugdevelopment company JSW-Research hasspecialised on the performance of experi-mental and clinical studies in the field ofneurodegenerative diseases. The enterprisehas internationally accepted expertise regar-

Alzheimer Parkinson Drug Development

Pain Inflammation

Pharmaceuticals

Contract Research Clinical Preclinical


AUSTRIAEXPORT


KompetenzzentrumMedizin GmbHLeopoldstraße 1/3A-6020 Innsbruck

T. +43/512/576526F. +43/512/576526-4320

GF Gordon [email protected]

www.kmt.at

Center for Life SciencesKMT is expanding its services in thearea of Life Sciences research

years, plant based medicines will become anadditional research focus. KMT manages largeresearch and co-operative programmes on anational and international level.

OUR SERVICESInternational and national research project management❚ Screening of national and EU calls❚ Project design, implementation and

management❚ Development of project proposals

Networking with industrial and academicpartners❚ Assistance in partner searches❚ Reporting on international trends and

trade shows

Consulting & Services❚ Finance and budgeting❚ Marketing and communications❚ Project management❚ Organisation of workshops, meetings and

conferences

Center of excellence❚ FP6 and upcoming FP7 – Life Sciences❚ Genomics and Biotechnology for Health❚ GEN-AU Projects❚ Interdisciplinary FTE projects, Austrian

Nano Initiative – Nano Diamond Network❚ fFORTE-FEMtech❚ K_ind / K_net Programmes❚ REGplus ❚

The Kompetenzzentrum Medizin Tirol(KMT) located in Innsbruck, Austria, wasfounded in 2002 and is an industrial centerof excellence for companies and researchinstitutions in the life sciences sector. Inno-vative research projects with high develop-ment and marketing chances are financedand managed by the KompetenzzentrumMedizin Tirol (KMT). The main areas of rese-arch are implant technology, bioanalytics,cell therapy and nano-(bio)technology. With regard to project management, KMThas specialist experience and expertise inproject planning, together with developingand managing project proposals, particularlyin the area of life sciences.As part of the contribution to the Europeanresearch agenda, KMT is extending its custo-mer services and promoting development ofthe Life Science Cluster Tirol at an interna-tional level. KMT, as a center of excellence,has well established contacts with key stake-holders (industry, academic, public autho-rities) in life sciences in the region andbeyond. The first results from research and develop-ment activities of some KMT projects havealready been successfully introduced onto themarket. The Tyrol region in Austria is particu-larly strong in the areas of cell therapy, immu-nology and bioanalytics. During the next few

Implant technology; bioanalytics; cell therapy; nano-(bio)technology.

Nano-(Bio)Technology and Bioanalytics

Phyto-Pharmaceutical, Cell Therapy and Implant Technology

Management of industrial research

Consulting and services


AUSTRIAEXPORT


Lambda GmbHIndustriestraße 6A-4240 Freistadt

T. +43/7942/75055-900F. +43/7942/75055-910

Mag. Florian [email protected]

Lambda GmbHLaboratory for Molecular-biologicalDNA Analysis

for quality assurance within the pharmaceu-tical industry. The combined expertise ofLambda and Greiner Bio-One comprises thedevelopment and production of a new inno-vative high-throughput biochip platform(High-Throughput microArraying, HTA™Slide) for the parallel analysis of samples, theselection of appropriate sequences and pro-bes and the validation and production of invitro diagnostics according to the EuropeanGuideline 98/79/EG and the internationalquality management standard EN ISO13485:2003 for medical devices, respective-ly. Products consist of complete test systemswith all the necessary buffers and solutions.The on-chip quality-control system, forwhich Lambda has already applied for apatent, guarantees perfect monitoring ofevery stage of analysis and production andtherefore virtually excludes false negativeand false positive results. An IVD-compatiblemicroarray scanner together with an integra-ted analysis software permit the fully auto-matic high-throughput detection and analy-sis of up to four biochips at once. TheLambda-products are distributed worldwideby Greiner Bio-One.

DNA AnalysisFor its customers, Lambda carries out a widerange of DNA analyses based on state-of-the-art technology. These include fatherhood tes-ting, detection of micro-organisms and ori-gin tests of meat products using external andin-house diagnostic products. ❚

The use and development of modern micro-technologies are opening up new opportuni-ties for medicine and research in the field ofdiagnostics. Since its foundation in the year1999, Lambda GmbH has responded to thechallenges in this field and now specializes ina wide range of molecular biological me-thods of detection. The innovative biotech-nology company with its roots in Freistadt,Austria, develops and produces biochips asready to use kits for applications in researchand routine diagnostics. DNA analysis andcustomer research work are carried out byexperienced specialists in Lambda's ownlaboratories. Through its close collaborationwith associates in industry and research,Lambda assures the practicality and reliabili-ty of its solutions. Thus, the company whichis owned by the Greiner Bio-One GmbH,develops biochips for the medical dia-gnostics.

Development and Production of BiochipsThrough their use in the screening of geneticdefects or infectious agents, biochips or"microarrays” represent one of the key tech-nologies of the future. Lambda develops andmanufactures high-quality biochips forhuman diagnostics, consumer protection and

MycoDtect™ - test kit for thedetection of Mycoplasma.

Diagnostics

DNA Analysis


Development and Production of DNA Chips


AUSTRIAEXPORT


Vienna School of ClinicalResearch

P.O. Box 109 Kölblgasse 10A-1031 Vienna

T. +43/1/713 40 51-0F. +43/1/713 40 51-99

[email protected]

A Centre of ExcellenceVienna School of Clinical Research(VSCR)

medical curricula in the world. The VSCR haspioneered a systematic postgraduate acade-mic education. The VSCR courses can be taken as individualshort courses to fill specific knowledge gaps.Several courses together form curricula thatare designed to meet the needs of investiga-tors, ethics committee members, clinicalresearch associates etc. These pre-defined cur-ricula are awarded diploma and widely recog-nized by academic centres. The current curri-culum for investigators comprises 9 coursemodules and awards graduates an academictitle, i. e. "Academically Certified ClinicalResearch Leaders". This programme is in theprogress of being extended towards a masterdegree which will be launched end of 2006.In order to compensate for the lack of inter-nationally binding guide-lines for the edu-cation of clinical researchers the VSCR'smission aims at:❚ Setting up a comprehensive education for

clinical researchers and for experts invol-ved in clinical studies

❚ Educating decision-makers within healthcare systems who must assure that theapplication of the research results is opti-mized and follows the principles of evi-dence-based medicine

❚ Obtaining international recognition of thiseducation from universities and authorities

❚ Supporting clinical research experts fromdeveloping regions by way of scholarshipsto open these regions for clinical researchdone according to international standards❚

The Vienna School of Clinical Research playsan exceptional role as a new centre for break-through learning opportunities in the field ofclinical research. The VSCR has become a"Centre of Excellence" for clinical researcheducation. Since its foundation in 2001,more than 1300 doctors as well as decisionmakers of public health authorities andmembers of ethics committees throughoutEurope, Middle East and Africa have com-pleted their postgraduate education in thearea of clinical research at the VSCR.The VSCR acts as a mediating institution bet-ween all interested parties including acade-mia, industry, the public sector and society.As a networking centre, the VSCR promotesan international interdisciplinary exchangein the biotechnological research field andcooperates trustfully with its partner-univer-sities to guarantee that the state-of-the-arteducation is based on academically recog-nized knowledge and. This cooperation isthe foundation of all educational activitiesundertaken by the VSCR.The international board of teachers consistsof representatives of the mentioned univer-sities as well as of leading experts of the rele-vant fields of expertise. The VSCR has step-ped into a vacuum-clinical research that isnot covered in the majority of the academic

Training and EducationResearch and Development


AUSTRIAEXPORT

Bioprocessing

ViruSure GmbHVeterinärplatz 1A-1210 Vienna

T. +43/1/25077 5960F. +43/1/25077 5961

Andy [email protected]

www.virusure.com

ViruSure GmbHQuality is not Coincidence!

of existing tests in modified formats. Technolo-gically, ViruSure aims to remain at the fore-front of virus and prion safety testing through:❚ a commitment of resources to research anddevelopment efforts in new tests and tech-nologies ❚ actively monitoring scientific andregulatory developments in virus and priontesting ❚ discussions with customers to fullyunderstand any potential adventitious agentrisks, and ensuring that the most appropria-te technologies are applied to address poten-tial risks

Technologies available include:❚ Virus or prion removal and inactivationstudies ❚ Quantitative real-time viral PCRassays ❚ Retrovirus assays (molecular and cellculture based) ❚ Cell culture based assaysgeneral virus assays ❚ In vivo tests for adventi-tious agents ❚ Prion in vitro and in vivo testsBased within the Vienna University ofVeterinary Medicine, Austria, ViruSure hasstrong alliances with various departmentsoffering expertise in animal based virus tes-ting as well as cell culture based assays. Wealso have a strong link with the laboratory ofProf. Bob Rohwer (Baltimore, Maryland, US),a reknowned expert in prion testing, andProf. Rohwer serves as a Scientific Advisorfor ViruSure.

To take advantage of our friendly and profes-sional service, please contact us through ourwebsite at www.virusure.com, or via email:[email protected]. ❚

ViruSure is an Austrian company with thegoal to become a world leader in contractvirus and prion safety testing. We have astrong commitment to customer service andquality, and have established the companystrategy and credo to help us achieve thisgoal. This includes:An Experienced Management TeamDeveloping an effective pathogen safety tes-ting program has always required significantinvestment of time and resources. This is achallenge difficult to achieve without expe-rience. At ViruSure we seek to maximise theavailable experience through the selection ofmanagement and Supervisory Board mem-bers ensuring that such experience is available.A Commitment to Quality and CustomerServiceAt ViruSure, our customers come first, andensuring that we deliver a quality servicecomes at the top of our list of priorities. Frominitial contact through development of a stra-tegy and implementation, a strong emphasison quality is present throughout. A qualityservice requires that staff are first aware ofthe standards that ViruSure sets with respectto customer service and quality. We thereforeplace a strong emphasis on staff training andcommunication of our strategies.Technological InnovationDeveloping the right strategy may require thedevelopment of new tests, or the application

In vivo and in vitro virus tests

Virus and Prion Removal Studies

Viral Safety Consultancy Services

Virus & Prion Safety Testing

Retrovirus testing


AUSTRIAEXPORT

Bioprocessing

VOGELBUSCH GmbHBlechturmgasse 11

A-1051 ViennaT. +43/1/546 61-0

F. +43/1/545 29 79Katharina Harlander

[email protected]

The Bioprocess Company

VOGELBUSCH – 85 years ofunrivalled excellence in bioprocess technology

VOGELBUSCH's range of services for thebiopharma industry focuses on fermentationwith cell cultures with and without carrier,as well as microbiological fermentations.Special stirring systems, an experienced, reli-able choice of components and profoundknow-how in sterile technology are the opti-mal pre-conditions to ensure flawless long-term functioning of fermentation processes.The company's complete product solutionincludes the reprocessing of the fermenta-tion products using the required utility faci-lities. VOGELBUSCH provides advanced con-cepts for all common downstream processesand the utilities typically used in the phar-maceutical industry. Vogelbusch’s expert team of specialized tech-nologists, biologists, chemists and engineershas gained an international reputation forflawless technology and expertise in biopro-cesses. The Vienna headquarters employ aworkforce of approximately 100 employees.Research and development is conducted inown laboratories and technological centres. With headquarters in Vienna and subsidia-ries in Houston, Texas and Hong Kong,VOGELBUSCH can provide professional cus-tomer services across the world ranging frominitial feasibility studies to turnkey installa-tion of production plants. Reference projectsthroughout the world are proof of abovestate-of-the-art technologies. Innovative andenvironmentally responsible process designshave contributed significantly to the successof VOGELBUSCH plants. ❚

Since 1921, the name VOGELBUSCH hasbeen synonymous for the engineering andconstruction of industrial plants using bio-technological processes. The company's activities focus on technolo-gies for the sugar, starch and food industries,and on plants and facility components forthe pharmaceutical industry. VOGELBUSCHprovides bioprocess design, consultancy andcontracting services, including scale-up andautomation, based on client processes as wellas on proprietary technology and apparatusdevelopment.The company is a centre of excellence for thekey biotechnological tasks of fermentation,separation, distillation and evaporation, andoffers a wide range of proprietary technolo-gies for the industrial production of biocom-modities, such as

❚ Alcohol (bioethanol, industrial alcohol,beverage alcohol)

❚ Yeast (baker’s yeast, fodder yeast)❚ Vinegar❚ Organic acids (citric acid, gluconic acid)❚ Glucose and HFS (High Fructose Syrup)

Technology revolves aroundknowledge - which means people.

Process Design

Technology

Consulting

Engineering


AUSTRIAEXPORT

Suppliers

Biomin GmbHIndustriestraße 21

A-3130 HerzogenburgT. +43/2782 / 803 0

F. +43/2782 / 803 30Kurt Wegleitner

[email protected]

Biomin – the natural wayBiomin is one of the key players in the international feed additivebusiness

Lithuania and France. As a result of Biomin´srapid expansion, the firm can offer its solu-tions to customers in more than 100 coun-tries worldwide.

Today Biomin cooperates with research faci-lities all over the world. Most of the compa-ny´s R&D is done at the IFA-Tulln in Austria.Constant improvements in R&D as well as astrictly monitored quality assurance programform the basis for best products for our cus-tomers.

This tight cooperation with Universities andIFA Tulln led to new inventions in differentfields. New plant protection products wereexplored, which fit into the philosophy ofBiomin to be best in quality, production, effi-cacy and for the environment. The recentlyfounded company bio-ferm is specialized onbiotechnological plant protection. The pro-duct Blossom Protect fb, based on antagonis-tic micro-organisms, is going to be registeredin the EU against fire blight, one of the mostdevastating plant diseases. Boni Protect is anatural way to protect spoilage of applesduring storage. ❚

Besides feed additives, the latest innovationfrom Biomin is a new feeding system calledthe "Biomin VBS”. The VarioBiotic Systemhelps customers to optimise the use of theirfeed additives and gives nutritional recom-mendations.

Biomin, the company that cares for health inanimal nutrition, was founded in 1983. Atthis time, the idea to support health ofanimals to ensure high performance wasunique.

The "3 men and 1 woman show” proved tobe on the right track. The company as well asthe product range grew fast.

In the nineties, Biomin started to expandworldwide, with the Mycofix Plus productseries as the first biotech product in mycoto-xin detoxification. In Asia, Biomin started upoffices in Malaysia, Singapore, Vietnam andChina, in America a sub-office was started inTexas and Romer Labs, a company speciali-sed in mycotoxin analysis, was taken over. InEurope, Biomin opened offices in Austria,Hungary, Slovakia, Romania, Germany,

Animal nutritionSuppliers


AUSTRIAEXPORT

Suppliers

CROMAPHARMA GmbHStockerauerstraße 181

A-2100 KorneuburgT. +43/2262/684 68-0

F. +43/2262/684 68-14Mag.pharm. Martin Prinz

[email protected]

CROMA-PHARMA GmbHEurope's leading filler ofviscoelastics

CONTRACT MANUFACTURING - See where innovation can take youCost pressures, globalization, complex pri-cing and regulatory environments are forcingpharmaceutical and biopharmaceutical com-panies to focus on improving operationalefficiency. Many companies have turned tooutsourcing as the solution. While most companies recognize the strategicimportance of outsourcing, many are not rea-ping its potential benefits. A centralizedmanagement structure is the key to makingthe most of contract manufacturing relation-ships and helps create consistency across thecompany. Maximize your contract manufac-turing relationships!

STRATEGIC PARTNERSHIPS - Mutually beneficial partnerships are a keyingredient in CROMA-PHARMA´s growthThe CROMA-PHARMA organisation is basedon alliances with its customers and their con-fidence in our line of products. That is whywe have formed close links with researchorganisations, university researchers andphysicians worldwide. CROMA-PHARMA´srapid expansion is also the result of coopera-tion with various companies in the industry.This close working relationship is built onshared competence, skill transfer, mutual res-pect and open communication. We realizecustomer visions beyond your expectations.Our philosophy is simple. A partnership witha client, that’s a natural fit – then do whateverit takes to show them breathtaking results. ❚

In this high-tech age, healthcare is faced withnumerous challenges: to provide high perfor-mance systems and devices, top-quality surgi-cal treatments as well as the maximum protec-tion. At CROMA-PHARMA we have met thischallenge with our innovative technologiesand product design, which ultimately improvethe quality of life for patients, makes surgicaltreatment easier for physician as well as forpersonnel. The power of innovation has ena-bled us to meet this challenge: to fullfill oursocial responsibility – to provide the best andthe safest viscoelastics and surgical fluids. Ourproducts and services are a sum of innovation,knowledge and experience. Life needs safety,we recognize our responsibility. Our success isbased on innovative ideas, state-of-the art tech-nologies and know-how to develop and manu-facture pharmaceutical systems such as sterilesyringes filled with viscoelastic solutions.

TECHNOLOGY - Focus on technologyCROMA-PHARMA applies state-of-the-artmanufacturing technology. Opened in 1994,the ultra modern manufacturing plant provi-des a constant flow of products from its fullyautomated production line. The site´s staff ofmanufacturing and engineering specialistsadhere to strict "Good ManufacturingPractice” standards in the production of over100 different products and millions of units.

Product Development

Contract Manufacturing

Viscoelastics

Ophthalmology, Orthopedics, Dermatology


AUSTRIAEXPORT

Suppliers

VTU-Engineering GmbHParkring 18

A-8074 Grambach/GrazT. +43/316/4009-200F. +43/316/4009-210

Dipl.-Ing. Robert [email protected]

www.vtu.com

High Tech Engineering

Biotechnology needs specializedengineering know-how

❚ Uncompromising orientation towardsthe customer’s benefit.In the end, the aim of all planning activitiesis the production of the desired product onan industrial scale. The extent and the pro-fundity of plant engineering are measuredby its quality and cost. Timely and localflexibility of application and frictionlesscooperation with our customer’s techniciansor engineering partner are self-evident.

❚ Highly qualified employees After having graduated at a University ofTechnology or an Advanced TechnicalCollege, our carefully chosen technicians(currently approx. 80 process engineers, che-mical engineers and bio engineers) receivecontinuous further training by attending spe-cific courses and seminars. In addition, ourknowledge management system secures thatknow-how is exchanged efficiently and thatinternal technical expertise is availablewithout delay. ❚

VTU Engineering is planning process plantsfor the pharmaceuticals, biotechnology andchemicals sectors of industry. Our activitiesfocus on process engineering and on com-plete project management - from the crea-tion of a concept up to final commissioning.For the pharmaceuticals industry we alsoperform qualification and validation servicesin accordance with cGMP, including the pro-vision of support during inspections andaudits. We have locations in Austria (Gram-bach/Graz, Linz, Vienna, Kundl), Germany(Frankfurt, Rheinbach/Bonn) and Italy (Bol-zano). Furthermore we are highly flexibleand willingly work at our customer’s sites.

Our costumers are medium-sized companiesas well as big players like Boehringer Ingel-heim, Degussa, DSM, Roche Diagnostics,Sandoz or Sanofi-Aventis.

The success of VTU-Engineering is based ontwo aspects:

Perfect solutions by a perfect team.

GMP-Qualification

Project Management

Conceptual Design

Basic Engineering


AUSTRIAEXPORT > LISTING

55pharma Drug Discovery & Development AGPalais PalffyA-1010 ViennaT. +43/1/219890 040F. +43/1/219890 [email protected]

Aesca Pharma GmbHBadener Straße 23A-2514 TraiskirchenT. +43/2252/502 0F. +43/2252/[email protected]

AFFIRIS Forschungs- und Entwicklungs GmbHCampus Vienna Biocenter 2A-1030 ViennaT. +43/1/7981575 10F. +43/1/7981575 [email protected]

Agneter PharmaConsulting GmbHMariahilfer Strasse 71/15A-1060 ViennaT. +43/1/5264244F. +43/1/5264366agneter@pharmaconsulting.atwww.pharmaconsulting.atPharmaceuticals page 16

AlcaSynn Pharmaceuticals GmbHLife Science Center, Mitterweg 24A-6020 InnsbruckT. +43/512/282 283 15F. +43/512/282 283 [email protected]

Alfa Laval Mid Europe GmbHIZ NÖ Süd Straße 2 / M7 / 1A-2355 Wr. NeudorfT. +43/2236/682 0F. +43/2236/[email protected]

Algavital Vertriebs GmbHRömerstraße 10A-2424 ZurndorfT. +43/2147/7000 200F. +43/2147/7000 [email protected]

ALK Abello Allergie-Service GmbHBäckermühlweg 59A-4030 LinzT. +43/732/385372 0F. +43/732/385372 [email protected]

Alvetra u.Werfft AGBoltzmanngasse 11A-1091 ViennaT. +43/1/3191456 0F. +43/1/3191456 [email protected]

Amynon BioTech GmbHInnrain 66/IIIA-6020 InnsbruckT. +43/512/50425 767F. +43/512/50425 [email protected] and Development, page 23

An der Grub Bio Research GmbHGerichtsberg 28, An der GrubA-2572 KaumbergT. +43/2765/597 0F. +43/2765/597 3

Angewandte Biotechnologie GmbHHellbrunnerstraße 34A-5020 SalzburgT. +43/662/639 61 0

Anstalt zur gewerblichen Produktion von Heilmittelnund Arzneiwaren GmbHSimmeringer Hauptstraße 24A-1110 ViennaT. +43/1/740 40 5769F. +43/1/740 40 [email protected]

Anton Paar GmbHAnton Paar Strasse 20A-8054 Graz-StrassgangT. +43/316/257 0F. +43/316/257 [email protected]

AOP Orphan Pharmaceuticals AGWilhelminenstrasse 91/II f/B4A-1160 ViennaT. +43/1/5037244F. +43/1/5037244 [email protected]

Apeiron Biologics Forschungs- und EntwicklungsGmbHBrunner Strasse 59A-1230 ViennaT. +43/1/865 65 77F. +43/1/865 65 77-9280office@apeiron-biologics.comwww.apeiron-biologics.comResearch and Development, page 24

Apomedica pharmazeutische Produkte GmbHRoseggerkai 3A-8010 GrazT. +43/316/823533F. +43/316/823533 [email protected]

Applera Austria Handels GmbHLiebermannstraße A01 303A-2345 Brunn/GebirgeT. +43/1/8673575 0F. +43/1/8673575 11austria.order@eur.appliedbiosystems.comwww.appliedbiosystems.com

Ars Arthro Biotechnologie GmbHMagnesistraße 1A-3500 KremsT. +43/2732/76954F. +43/2732/76954 [email protected]

Ash Dec Umwelt AGDonaufelder Straße 101/4/5A-1210 ViennaT. +43/1/7344640F. +43/1/7344640 [email protected]

Astellas Pharma Ges.m.b.H.Linzerstrasse 221 E 02A-1140 ViennaT. +43/1/8772668 0F. +43/1/[email protected]

Aureon Biosystems GmbHSimmeringer Hauptstraße 24A-1110 ViennaT. +43/1/740 40 350F. +43/1/740 40 [email protected]

Aurora Feinchemie GmbH, Kutyrev Alexandre, Dr.Reininghausstraße 49A-8020 GrazT. +43/316/58 67 38F. +43/316/58 47 [email protected]

Austrian Energy & Environment AGWaagner-Biro-Platz 1A-8074 RaabaT. +43/316/501 0F. +43/316/501 [email protected]

Austrianova Biotechnologie GmbHVeterinärpl. 1, Gebäude AC-2. StockA-1210 ViennaT. +43/1/25077 2601F. +43/1/25077 [email protected]

Austroplant-Arzneimittel Gesellschaft m.b.H.Richard-Strauss-Strasse 13A-1232 ViennaT. +43/1/61626440F. +43/1/[email protected]

Aventis Pasteur MSD GmbHLemböckgasse 49/2/Top E 5–2A-1230 ViennaT. +43/1/61 04 70F. +43/1/61 67 97 [email protected]

Aventis Pharma GmbHLeonardbernsteinstraße 10A-1220 ViennaT. +43/1/801 85 0F. +43/1/801 85 [email protected]

Axon Neuroscience Forschungs- undEntwicklungsgmbHRennweg 95 BA-1030 ViennaT. +43/1/7966898F. +43/1/7966898 [email protected]/

Bano Mag. Josef Chem.-Pharm. PräparateIm Gries 22A-6580 St. Anton am Arlberg

T. +43/5446/2061F. +43/5446/2061 [email protected]

BASF Österreich GmbHKolingasse 12A-1090 ViennaT. +43/1/878 90 0F. +43/1/878 90 [email protected]

BAXTER AG Bio Science ViennaIndustriestrasse 67A-1221 ViennaT. +43/1/20 100-0F. +43/1/20 [email protected]

Bayer Austria GesmbHLerchenfelder Gürtel 9–11A-1164 ViennaT. +43/1/711 46 0F. +43/1/711 46 14www.bayer.at

BDF Beiersdorf GesmbHLaxenburgerstraße 151A-1100 ViennaT. +43/1/614000 317F. +43/1/61400 [email protected]

Bender MedSystems GmbHCampus Vienna Biocenter 2A-1030 ViennaT. +43/1/796 4040 106F. +43/1/796 4040 [email protected]

Biodesign Consulting engineering GmbHAn der Scheibenwiese 1/2/9A-1160 ViennaT. +43/1/9111344F. +43/1/9111344

BioDevelops Pharma Entwicklung GmbHBrunner Straße 59/59A-1230 ViennaT. +43/1/710661 6F. +43/1/710661 [email protected]

Biodiesel Kärnten GmbHIndustriestrasse 29A-9601 ArnoldsteinT. +43/4255/908 12 21F. +43/4255/908 12 [email protected]

Bioenergetik Rechberger KEGLöwengasse 40/2/3A-1030 ViennaT. +43/1/966 9663F. +43/1/966 [email protected]

biolution Grünert & Co KEGStutterheimstrasse 16-18A-1150 ViennaT. +43/1/7869595F. +43/1/7869595 [email protected]

BIOMAY AGLazarettgasse 19 Top 1A-1090 ViennaT. +43/1/796 62 96 100F. +43/1/796 62 96 [email protected]

Biomechanische Forschungs-Gesellschaft m.b.H.Rechte Viennazeile 5/2A-1043 ViennaT. +43/1/586 64 46 0F. +43/1/586 64 [email protected]

BIOMEDICA Medizinprodukte GmbH & CO KGDivischgasse 4A-1210 ViennaT. +43/1/291 07 11F. +43/1/291 07 [email protected]

Biomin GmbHIndustriestrasse 21A-3130 HerzogenburgT. +43/2783/803 0F. +43/2783/803 [email protected], page 35

Biopure Referenzsubstanzen GmbHTechnopark 1A-3430 TullnT. +43/2272/615 33 20F. +43/2272/615 33 211

[email protected], page 21

BIOS BIOENERGIESYSTEME GmbHInffeldgasse 21bA-8010 GrazT. +43/316/481 300 27F. +43/316/481 [email protected]

Biotec Systems Krems GmbHMagnesitstraße 1A-3500 KremsT. +43/2732/82 699 0F. +43/2732/82 699 [email protected]

Biotechnology ConsultingWilhelminenstraße 95(BLOCK C)/17A-1160 ViennaT. +43/1/4810987F. +43/1/664 [email protected]

Biovertis - Information Driven Drug Design AGCampus Vienna Biocenter 6A-1030 ViennaT. +43/1/798 93 03F. +43/1/789 93 [email protected]://biovertis.com

Biovest Consulting GmbHLerchenfelderstr. 88–90/22A-1080 ViennaT. +43/1/9233048F. +43/1/[email protected]

Biozym GmbHBiochemiestraße 10A-6250 TirolT. +43/5338/200 0F. +43/5338/200 [email protected]

Bittner Pharma - Richard Bittner AG, Büro ViennaKärntner Ring 11–13A-1010 ViennaT. +43/1/503 09 72F. +43/1/503 09 [email protected]

BMT Medizinische Forschung und Entwicklung GmbHBrunnerstraße 59/5A-1235 ViennaT. +43/1/867 36 91F. +43/1/867 36 [email protected]

Boehringer Ingelheim Austria GmbHDr. Boehringer-Gasse 5–11A-1121 ViennaT. +43/1/80105-2141F. +43/1/80105-2440monika.henninger@vie.boehringer-ingelheim.comwww.boehringer-ingelheim.atPharmaceuticals, page 17

Boehringer Ingelheim Pharma GesmbHDr. Boehringer Gasse 5–11A-1121 ViennaT. +43/1/801 05 0F. +43/1/804 08 [email protected]

Brady C.Hörlgasse 5A-1090 ViennaT. +43/1/3106960F. +43/1/3106960 [email protected]

Bunge Austria GmbHIndustriegelände West 3A-2460 Bruck an der LeithaT. +43/2162/606 0F. +43/2162/606 [email protected]

C4 Holding AGTuchlauben 8A-1010 ViennaT. +43/1/5327888F. +43/1/5327888 [email protected]

Carl Zeiss GmbHModecenterstraße 16A-1030 ViennaT. +43/1/795 18 0F. +43/1/795 18 [email protected]

C

B

A



CeMM - Forschungszentrum für molekulare MedizinGmbHLazaretgasse19A-1090 ViennaT. +43/1/401 60 70 01 1F. +43/1/401 60 97 00 [email protected]

Chemgineering Planung GmbHPerfektastraße 45A-1230 ViennaT. +43/1/2557413F. +43/1/2557413 [email protected]

Chemomedica Medizintechnik u. ArzneimittelVertriebsgmbHWipplingerstraße 19A-1010 ViennaT. +43/1/53326660F. +43/1/[email protected]

Chepharin Chemisch- pharmazeutische IndustrieGmbHFlatschacher Straße 57A-9020 KlagenfurtT. +43/463/316 35 0F. +43/463/316 35 [email protected]

CIS Clinical Investigation Support PharmaforschungGesellschaft m.b.H.Kaiserstrasse 43A-1070 ViennaT. +43/1/523 40 15F. +43/1/523 40 [email protected] and Development, page 25

CNSystems Medizintechnik GmbHReininghausstrasse 13A-8020 GrazT. +43/316/723456F. +43/316/723456 [email protected]

CoaChrom Diagnostica GmbHStolzenthalergasse 6A-1080 ViennaT. +43/1/6999797 0F. +43/1/[email protected]

CROMA PHARMA GmbHStockerauerstrasse 181A-2100 KorneuburgT. +43/2262/684 68 0F. +43/2262/684 68 [email protected], page 36

Donau Chemie AGAm Heumarkt 10A-1030 ViennaT. +43/1/71147 0F. +43/1/71147 [email protected]

Doskar Martin Mag.Schottenring 14A-1013 ViennaT. +43/1/5353724 23F. +43/1/5353724 [email protected]

Dr. A. & L. Schmidgall KGWolfganggasse 45–47A-1120 ViennaT. +43/1/811 58 0F. +43/1/811 58 [email protected]

Dr. Kolassa & Merz GesmbHGastgebgasse 5-13A-1230 ViennaT. +43/1/8691604 0F. +43/1/8691604 [email protected]

Dr. Oliver DinstlTelekygasse 15A-1190 [email protected]

DSM Fine Chemicals Austria Nfg GmbH & Co KGSt.Peter Straße 25A-4020 Linz, DonauT. +43/732/6916 0F. +43/732/6916 [email protected]

EBEWE Pharma GmbH Nfg.KGMondseestraße 11A-4866 Unterach am AtterseeT. +43/7665/8123 0F. +43/7665/8123 [email protected]

EccoCell Biotechnologie GmbHKörblergasse 42 (Sanatorium Hansa)A-8010 GrazT. +43/316/722866 13F. +43/316/722866 [email protected]

ECOWORK LABORATORIES Consulting GmbHBrehmstraße 14 AA-1110 ViennaT. +43/1/606 45 95F. +43/1/606 45 95 [email protected]

Eichenauer`s KräuterparadiesEichendorffstrasse 58A-4020 [email protected]

Eli Lilly GesmbHBarichgasse 40–42A-1030 ViennaT. +43/1/71178-0F. +43/1/[email protected]

emergentec biodevelopment GmbHRathausstrasse 5/3A-1010 ViennaT. +43/1/4034966F. +43/1/403 49 [email protected]

EUCODIS GmbHBrunner Strasse 59A-1230 ViennaT. +43/1/866 34 9240F. +43/1/866 34 [email protected], [email protected] and Development, page 26

Ezinger Ing. August Biochemische ErzeugnisseUnterpramau 1A-4775 Taufkirchen an der PramT. +43/7719/7517F. +43/7719/[email protected]

Faromed GmbHJohann Strauß-Gasse 7/5A-1040 ViennaT. +43/1/50574740F. +43/1/[email protected]

Ferdinand Menzl MedizintechnikDonaufelderstrasse 189A-1220 ViennaT. +43/1/255 89 60F. +43/1/255 89 60 [email protected]

Fibrex Medical Research & Development GmbHBrunnerstr. 59A-1235 ViennaT. +43/1/86634-9270F. +43/1/86634-9279rainer.henning@fibrexmedical.comwww.fibrexmedical.comResearch and Development, page 27

Forschungsinstitut für molekulare Pathologie GmbHDr. Bohrgasse 7A-1030 ViennaT. +43/1/797 30 0F. +43/1/798 71 [email protected]

G.L. Pharma GmbHSchloßplatz 1A-8502 LannachT. +43/3136/82577F. +43/3136/[email protected]

GAT Formulation GmbHGewerbezone 1A-2490 EbenfurthT. +43/2624/53922F. +43/2624/53922 [email protected]

gcp gamma capital partners Beratungs- &Beteiligungs GmbHMarokkanergasse 22/7A-1030 ViennaT. +43/1/513 10 [email protected]

Gebro Pharma GmbHBahnhofbichl 11A-6391 FieberbrunnT. +43/5354/53000F. +43/5354/[email protected]

GenoSense Diagnostics GmbHRennweg 95 B Ebene 5A-1030 ViennaT. +43/1/7966572 90F. +43/1/2530253 [email protected]

Gepa-Med Medizintechnik GmbHSprengersteig 4A-1160 ViennaT. +43/1/4896353F. +43/1/4896353 [email protected]

Germania Pharmazeutika GesmbHSchuselkagasse 8A-1150 ViennaT. +43/1/982 33 99F. +43/1/982 33 99 [email protected]

Gerot Pharmazeutika GmbHArnethgasse 3A-1160 ViennaT. +43/1/485 35 05 0F. +43/1/485 77 [email protected]

GLOBOPHARM Pharmazeutische Produktions- undHandels GesmbHBräunlichg.40–42A-2700 Wr. NeustadtT. +43/1/8031727 373F. +43/1/8031727 [email protected]

Green Hills Biotechnology Research DevelopmentTrade GmbHGersthoferstr. 29–31A-1180 ViennaT. +43/1/3199670F. +43/1/3199670 [email protected]

HÄMOSAN Life Science Services GmbHNeudorf 41A-8262 IlzT. +43/3385/8117F. +43/3385/8117 [email protected]

Harichem Chemische Produkte GmbHBayergasse 1/7A-1030 ViennaT. +43/1/710 47 47F. +43/1/710 47 [email protected]

Hauser Paul Herba Apotheken AGFlatschacher Straße 57A-9020 KlagenfurtT. +43/463/38300F. +43/463/3830 [email protected]

Henkel Central Eastern Europe GmbHErdbergstraße 29A-1030 ViennaT. +43/1/711 04 0F. +43/1/711 04 [email protected]

HITT-health information technolgies tirolLeopoldstraße 1A-6020 InnsbruckT. +43/512/576523F. +43/512/576523 [email protected]

HL Dr. Hans Loibner Bioscience Research GmbHBrunner Straße 59A-1230 ViennaT. +43/1/888 76 15F. +43/1/888 76 [email protected]

Human.technology Styria GmbHReininghausstrasse 13A-8020 GrazT. +43/316/587016-0F. +43/316/587016-16

[email protected], www.human.technology.atpage 11

I-Med Laboratory of Tumor Immunology ; Children'sCancer Research InstituteKinderspitalgasse 6A-1090 ViennaT. +43/1/401 70-0F. +43/1/408 7230

I.T.S. Implantat-Technologie-Systeme GmbHAutal 28A-8301 LaßnitzhöheT. +43/316/211210F. +43/316/[email protected]

IGENEON Krebs-Immuntherapie Forschungs- undEntwicklungs-GmbHBrunner Strasse 69, Objekt 3A-1230 ViennaT. +43/1/90250 0F. +43/1/90250 [email protected]

igor - Institut für Gewebe und OrganrekonstruktionGes.m.b.H.Bernadingasse 12A-4600 WelsT. +43/7242/4412820F. +43/7242/[email protected]

Immodal Pharmaka GesmbHBundesstraße 44A-6111 VoldersT. +43/5224/57678F. +43/5224/[email protected]

INGENETIX Vertriebs GmbHMariahilferstraße 5/8A-1060 ViennaT. +43/1/585 80 91F. +43/1/585 80 [email protected]

Innovacell Biotechnologie GmbHMitterweg 24A-6020 InnsbruckT. +43/512/573680F. +43/512/573680 [email protected]

INOVIA Hutzinger GmbH & Co KGEdtholz 21A-4600 WelsT. +43/7242/350159 0F. +43/7242/350159 [email protected]

Insight Instruments Dr. Dieter KropfreiterSteglandweg 5A-5400 HalleinT. +43/6245/71149F. +43/6245/[email protected]

INSILICO Software GmbHDonau-City-Straße 1, Gate 3/4.StockA-1220 ViennaT. +43/1/2051224F. +43/1/2051224 [email protected]

Institute of Molecular Biotechnology of the AustrianAcademy of Sciences (IMBA)Dr. Bohr-Gasse 7A-1030 ViennaT. +43/1/79730 456F. +43/1/79730 459www.imba.oeaw.ac.at

Inte:Ligand Software-Entwicklungs und ConsultingGmbHClemens Maria Hofbauer-G. 6A-2344 Maria EnzersdorfT. +43/2236/650 374 83 47F. +43/2236/650 374 83 47 [email protected]

INTERCELL AGCampus Vienna Biocenter 6A-1030 ViennaT. +43/1/20620 0F. +43/1/20620 [email protected]

Ionimed Analytik Ges. m.b.H.Technikerstraße 21aA-6020 InnsbruckT. +43/512/507-4810F. +43/512/[email protected] and Development, page 28

I

H

G

F

E

D



JSW-Research Forschungslabor GmbHRankengasse 28aA-8020 GrazT. +43/316/76 51 14-22F. +43/316/76 51 14 [email protected]@jswresearch.comwww.jswresearch.comResearch and Development, page 29

Jungbunzlauer Austria AGSchwarzenbergplatz 16A-1010 ViennaT. +43/1/50200F. +43/1/50200 [email protected]

Kendro Laboratory Products GesmbHWiegelestraße 4A-1230 ViennaT. +43/1/80140 0F. +43/1/80140 [email protected]

Kompetenzzentrum Medizin GmbHLeopoldstraße 1/3A-6020 InnsbruckT. +43/512/576526F. +43/512/[email protected] and Development, page 30

Kplus ECHEMViktor Kaplan Straße 2A-2700 Wr. NeustadtT. +43/2622/[email protected]

Kühne Christian Dr. Dipl.-Ing.Zeinlhofergasse 6/18A-1050 ViennaT. +43/1/581 34 62

Kwizda Pharma GmbHEffingergasse 21A-1160 ViennaT. +43/5/99 77 30 0F. +43/5/99 77 30 [email protected]

Labor f. Immunologie u. Immuntherapie derUniversitätsklinik f. Urologie, MedizinischeUniversität InnsbruckAnichstraße 35A-6020 InnsbruckT. +43/5/05 04 24867F. +43/5/05 04 [email protected]

LACTOSAN, Starterkulturen Gesellschaft m.b.H. & Co.KGIndustrie- und GewerbeparkA-8605 KapfenbergT. +43/3862/32602F. +43/3862/32602 [email protected]

Lambda GmbHIndustriestraße 6A-4240 FreistadtT. +43/7942/75055-900F. +43/7942/[email protected] and Development, page 31

Lannacher Heilmittel GesmbHSchloßplatz 1A-8502 LannachT. +43/3136/82577F. +43/3136/[email protected]

Life Optics GmbHSeeböckgasse 59A-1160 ViennaT. +43/1/478 99 10F. +43/1/478 99 [email protected]

Life Science Austria (LISA) Vienna RegionEbendorferstraße 4A-1010 ViennaT. +43/1/4000-86934F. +43/1/[email protected] 12

Lifecrystal Gesundheitsprodukte GmbHBreitenfelderstraße 18 aA-5020 SalzburgT. +43/662/87 21 27

F. +43/662/87 21 [email protected]

Mayrhofer Pharmalogistik GmbHDr. Karl Lueger-Ring 6A-1010 ViennaT. +43/5/997726 0F. +43/5/997726 [email protected]

Med-El Elektromedizinische Geräte GmbHFürstenweg 77aA-6020 InnsbruckT. +43/512/288889F. +43/512/[email protected]

Medimplant Medizinisch-Technische Geräte GesmbHLaudongasse 10A-1080 ViennaT. +43/1/4086848F. +43/1/[email protected]

Medizinische Universität GrazUniversitätsplatz 3A-8010 GrazT. +43/3182/380 [email protected]

MELASAN Produktions- und Vertriebsges.m.b.H.Nordstraße 1A-5301 EugendorfT. +43/6225/28405F. +43/6225/28405 [email protected]

Merck GmbHZimbagasse 5A-1147 ViennaT. +43/1/576000F. +43/1/[email protected]

Merck GmbH Werk SpittalHößlgasse 20A-9800 Spittal/DrauT. +43/4762/5151-0F. +43/4762/5151 [email protected]

Metochem Pharma GesmbHJochen Rindt Straße 23A-1239 ViennaT. +43/1/6168425 0F. +43/1/6168425 [email protected]

Michael Weinzierl GmbHEuroparing F 12/401A-2345 Brunn am GebirgeT. +43/2236/31 22 31F. +43/2236/31 22 [email protected]

Michael ZamponiBurgg 43A-8750 JudenburgT. +43/3572/84381F. +43/3572/[email protected]

Molekulare Biotechnologie GmbHMariagrünerstraße 91A-8043 GrazT. +43/316/873 84 [email protected]

Mr. pharm. Josef. W.Wenig, Pharm. chem. ErzeugungGesmbHVan der Nuellgasse 22A-1100 ViennaT. +43/1/6041490 0F. +43/1/6041490 [email protected]

Mr.Petrasch GesmbH & CO Chem.Pharm.FabrikSchlachthausstraße 3A-6850 DornbirnT. +43/5572/227 29F. +43/5572/227 29 [email protected]

MTI Maize Technologies International GmbHLudwig Boltzmann Straße 2A-7100 NeusiedlT. +43/5/9010 8170F. +43/5/9010 [email protected]

Mucobiomer Biotechnologische Forschungs- undEntwicklungs GmbHIndustriezeile 6A-2100 Leobendorf

T. +43/2262/68409 0F. +43/2262/68409 [email protected]

Mycosafe Diagnostics GmbHVeterinaerplatz 1, Campus University of VeterinaryMedicine ViennaA-1210 ViennaT. +43/1/250 77-2150F. +43/1/250 [email protected], page 18

Nabriva Therapeutics Forschungs GmbHBrunnerstraße 59A-1235 ViennaT. +43/1/86659F. +43/1/866 [email protected]

Nano S Biotechnologie GmbHGregor Mendelstrasse 33,A-1180 ViennaT. +43/1/47654 2219F. +43/1/47654 [email protected]

Neuberger ResearchPraterstraße 43/3/15A-1020 ViennaT. +43/1/7869390F. +43/1/[email protected]

Novartis Institutes for BioMedical Research GmbH &Co KGBrunner Straße 59A-1235 ViennaT. +43/1/866 34-0F. +43/1/866 [email protected]

NOVA TECHnical Research GmbHWohllebengasse 10/7A-1040 ViennaT. +43/1/503 16 89F. +43/1/503 53 [email protected]

NOWICKY PHARMAMargaretenstrasse 7A-1040 ViennaT. +43/1/5861223F. +43/1/[email protected], page 19

Nycomed Austria GmbHSt.Peter Straße 25A-4021 Linz, DonauT. +43/732/69 19 0F. +43/732/65 55 [email protected]

Obwaller Forschungs- und Entwicklungs GmbHStutterheimstraße 16-18/2/1A-1150 ViennaT. +43/1/890 14 11F. +43/1/890 14 11 [email protected]

Octapharma Pharmazeutika Produktions GesmbHOberlaaer Straße 235A-1100 ViennaT. +43/1/61032 0F. +43/1/61032 [email protected]

onepharm Research & Development GmbHGersthoferstraße 29–31A-1180 [email protected]

OÖ. Technologie- und Marketinggesellschaft m.b.H.Hafenstraße 47–51A-4020 LinzT. +43/732/7981-5005F. +43/732/[email protected] page 13

Oridis Biomed Forschungs- und Entwicklungs GmbHStiftingtalstr. 3–5A-8010 GrazT. +43/316/325 776F. +43/316/325 776 [email protected]

Österreichische Ichthyol GmbH Nunmehr KGMaximilianshütteA-6100 Reith bei SeefeldT. +43/5212/2204

F. +43/5212/2204 [email protected]

P.P.M. Energie aus nachwachsenden RohstoffenGmbHMühlengasse 5A-3041 AsperhofenT. +43/2772/584 11F. +43/2772/519 [email protected]

PAA Laboratories GmbHHaidmannweg 9A-4061 PaschingT. +43/7229/64865F. +43/7229/[email protected]

Pelias Biotechnologies GmbHDannebergplatz 16/2A-1030 ViennaT. +43/1/7180326 326F. +43/1/7180326 800www.pelias.com

Pfizer Corporation Austria GmbHFloridsdorfer Hauptstraße 1A-1210 ViennaT. +43/1/521 150F. +43/1/526 91 [email protected]

Pharmazeutische Fabrik Montavit GmbHSalzbergstraße 96A-6067 AbsamT. +43/5223/579 26 0F. +43/5223/579 26 [email protected]

Pharmonta Dr. Fischer GmbHMontanastraße 7A-8112 GratweinT. +43/3124/51368-0F. +43/3124/[email protected]

Philips Austria GmbH, Werk KlagenfurtKoningsbergerstraße 11A-9020 KlagenfurtT. +43/463/3866F. +43/463/3866 [email protected]

piCHEM Forschungs-und Entwicklungs GmbHKahngasse 20A-8045 Graz-AndritzT. +43/316/681 71 10F. +43/316/681 71 [email protected]

Pioneer Hi-Bred Services GmbHPioneerstraße IndustriegeländeA-7111 ParndorfT. +43/2166/2525 0F. +43/2166/2525 [email protected]

Pirich Eberhard Dr., PR Beratung imGesundheitswesenFelix Mottl-Straße 32A-1190 ViennaT. +43/1/3680850F. +43/1/3680850 [email protected]

PLANTA Naturstoffe Vertriebsges.m.b.H.Erlgasse 48A-1120 ViennaT. +43/1/8105366F. +43/1/8105366 [email protected]

Polymun Scientific Immunbiologische ForschungGesmbHNußdorfer Lände 11A-1190 ViennaT. +43/1/36006 6202F. +43/1/[email protected]

Porr Umwelttechnik GmbHAbsberggasse 47A-1100 ViennaT. +43/5/626 2010F. +43/5/626 [email protected]

ProtAffin Biotechnologie AGImpulszentrum Graz-West,A-8020 GrazT. +43/316/380 53 73F. +43/316/380 25 [email protected]

P

O

N

M

L

K

J


AUSTRIAEXPORT > LISTING • INDEX

Quantas Analytics GmbHTechnopark 1A-3430 TullnT. +43/2272/615 33 30F. +43/2272/615 33 [email protected], page 21

Quintiles GesmbHGuglgasse 7–9/B/OG 6A-1030 ViennaT. +43/1/7263010F. +43/1/7263010 [email protected]

rho-BeSt coating Hartstoffbeschichtungs GmbHErlach 165A-6150 Steinach am BrennerT. +43/5272/6269F. +43/5272/6269 [email protected]

Richter Pharma AGFeldgasse 19A-4600 WelsT. +43/7242/4900F. +43/7242/[email protected]

Roche Diagnostics GesmbHEngelhorngasse 3A-1211 ViennaT. +43/1/27787 0F. +43/1/27787 [email protected]

Romer Labs Diagnostic GmbHTechnopark 1A-3430 TullnT. +43/2272/6153310F. +43/2272/[email protected], page 21

Rösch & Handel Vorm. Gimborn & Co GmbH & Co KGGudrunstraße 150A-1100 ViennaT. +43/1/60414900F. +43/1/[email protected]

Salzmann Ingenieubüro GmbHAngelika Kauffmann Straße 5A-6900 BregenzT. +43/5574/45524 0F. +43/5574/45524 [email protected]

Sandoz GmbHBiochemiestraße 10A-6250 KundlT. +43/5338/200-0F. +43/5338/[email protected]

Sandoz GmbH ViennaWagramer Straße 19A-1220 ViennaT. +43/1/26068 0F. +43/1/26068 [email protected]

Sanochemia Pharmazeutica AGBoltzmanngasse 11A-1091 ViennaT. +43/1/3191456-0F. +43/1/3191456 [email protected], page 20

Schering Austria GmbHViennaerbergstraße 41A-1121 ViennaT. +43/1/970 37 0F. +43/1/970 37 [email protected]

SCIOTEC Diagnostic Technologies GmbHSimmeringer Hauptstraße 24A-1110 ViennaT. +43/1/740 403 61F. +43/1/740 403 [email protected]

Seeg-Südsteirische Energie u. EiweisserzeugungReg.Gen.mbHPestkreuzweg 3A-8480 MureckT. +43/3472/3577 0F. +43/3472/[email protected]/seeg.php

Solvay Vienna GmbHStättermayergasse 28–30A-1150 ViennaT. +43/1/716880F. +43/1/[email protected]

Spagyra KG Ph. Mr. Heinrich Sedlar Pharm.-biologi-sche PräparateMarktplatz 5AA-5082 GrödigT. +43/6246/72370F. +43/6246/[email protected]

SY-LAB Geräte GmbHTullnerbachstraße 61–65A-3011 Neu-PurkersdorfT. +43/2231/62252F. +43/2231/[email protected]

Tecan Austria GmbHUntersbergstraße 1AA-5082 GrödigT. +43/6246/89 33F. +43/6246/727 [email protected]

Technoclone Herstellung von Diagnostika undArzneimitteln Gesellschaft m.b.H.Brunner Straße 59/5A-1235 ViennaT. +43/1/863 73 0F. +43/1/863 73 [email protected]

Technopol KremsMagnesitstraße 1A-3500 KremsT. +43/2732/87470-230F. +43/2732/[email protected]/technologypage 14

Technopol TullnTechnopark 1A-3430 TullnT. +43/2272/61375-10F. +43/2272/[email protected]/technologypage 14

ThioMatrix Forschungs- und Beratungs GmbHUnterer Platz 22A-9300 St. Veit an der GlanT. +43/4212/[email protected]

Tiroler ZukunftsstiftungKaiser-Jäger-Straße 4aA-6020 InnsbruckT. +43/512/576262F. +43/512/[email protected] 15

TissueGnostics GmbHTaborstraße 10/2/8A-1020 ViennaT. +43/1/2161190F. +43/1/2161190 [email protected]

Topo-Pharma Forschungs- und Produktionsges.m.b.H.Gartengasse 8A-1053 ViennaT. +43/1/5451235 0F. +43/1/5451235 [email protected]

ugichem Gesellschaft für organische Chemie mbHMitterweg 24A-6020 InnsbruckT. +43/512/282 285 10 40F. +43/512/282 285 [email protected]

Ulbing Ilse MariaNeutorgasse 22A-8010 GrazT. +43/316/38 37 46F. +43/316/38 37 [email protected]

Vana GmbHWolfgang-Schmälzl-Gasse 6A-1020 ViennaT. +43/1/728 036 70F. +43/1/728 0367 [email protected]

VBC-Genomics Bioscience Research GmbHRennweg 95BA-1030 ViennaT. +43/1/796 65 72F. +43/1/796 65 72 [email protected]

VBC Vienna Bio Center Errichtungs GmbHRathausplatz 2A-1010 ViennaT. +43/1/4000 86172F. +43/1/4000 [email protected]

Viatris Pharma GmbHLiesinger Flur-Gasse 2cA-1230 ViennaT. +43/1/86 390 0F. +43/1/86 390 [email protected]

Vienna School of Clinical ResearchKölblgasse 10, P.O. Box 109A-1031 ViennaT. +43/1/713 40 51-0F. +43/1/713 40 [email protected] and Development, page 32

ViennaLab Labordiagnostika GmbHAm Kanal 27A-1110 ViennaT. +43/1/74040190F. +43/1/[email protected]

ViruSure GmbHVeterinärplatz 1A-1210 ViennaT. +43/1/25077 5960F. +43/1/25077 [email protected], page 33

vitateq biotechnology GmbHInnrain 66A-6020 InnsbruckT. +43/512/504 25590F. +43/512/504 [email protected], page 22

Vitro Plant Pflanzen-Biotechnologie GmbHBrunnleiten 17A-3400 KlosterneuburgT. +43/2243/326 980F. +43/2243/257 [email protected]

Vogelbusch GmbHBlechturmgasse 11A-1050 ViennaT. +43/1/546610F. +43/1/5452979office@vienna.vogelbusch.comwww.vogelbusch.comBioprocessing, page 34

VTA Engineering u. Umwelttechnik GmbHHauptstraße 2A-4675 WeibernT. +43/7732/41 33 0F. +43/7732/22 [email protected]

VTU-Engineering GmbHParkring 18A-8074 Grambach/GrazT. +43/316/4009-200F. +43/316/[email protected], page 37

VTU-Engineering Planungs- undBeratungsgesellschaft m.b.H.Parkring 18A-8074 GrambachT. +43/316/4009200F. +43/316/[email protected]

Zechner Gisela Dipl.-Ing.Breitenseer Straße 49/3/4A-1140 ViennaT. +43/1/98 54 276F. +43/1/98 31 [email protected]

Zeta Anlagenbau GmbHParacelsusweg 1A-8144 TobelbadT. +43/3136/9010-0F. +43/3136/[email protected]

ZLB Behring GmbHAltmannsdorferstraße 104A-1120 ViennaT. +43/1/801 01 2463F. +43/1/801 01 [email protected]

Zuckerforschung Tulln GmbHJosef-Reither-Straße 21–23A-3430 TullnT. +43/2272/602402F. +43/2272/[email protected]

INDEX

Agneter PharmaConsulting GmbH, page 16Boehringer Ingelheim Austria GmbH, page 17Fibrex Medical Research & Development GmbH, page 27JSW-Research Forschungslabor GmbH, page 29Mycosafe Diagnostics GmbH, page 18NOWICKY PHARMA, page 19Sanochemia Pharmazeutica AG, page 20

Amynon BioTech GmbH, page 23Biopure Referenzsubstanzen GmbH, page 21Lambda GmbH, page 31Quantas Analytics GmbH, page 21Romer Labs Diagnostic GmbH, page 21Sanochemia Pharmazeutika AG, page 20vitateq biotechnology GmbH, page 22

Agneter PharmaConsulting GmbH, page 16Amynon BioTech GmbH, page 23Apeiron Biologics Forschungs- und Entwicklungs GmbH, page 24Biopure Referenzsubstanzen GmbH, page 21CIS Clinical Investigation Support PharmaforschungGesellschaft m.b.H., page 25EUCODIS GmbH, page 26Fibrex Medical Research & Development GmbH, page 27Ionimed Analytik Ges. m.b.H., page 28JSW-Research Forschungslabor GmbH, page 29Kompetenzzentrum Medizin GmbH, page 30Lambda GmbH, page 31Mycosafe Diagnostics GmbH, page 18Quantas Analytics GmbH, page 21Romer Labs Diagnostic GmbH, page 21Sanochemia Pharmazeutika AG, page 20Vienna School of Clinical Research, page 32vitateq biotechnology GmbH, page 22

ViruSure GmbH, page 33Vogelbusch GmbH, page 34

Biomin GmbH, page 35Biopure Referenzsubstanzen GmbH, page 21CROMA PHARMA GmbH, page 36Quantas Analytics GmbH, page 21Romer Labs Diagnostic GmbH, page 21vitateq biotechnology GmbH, page 22VTU-Engineering GmbH, page 37

Human.technology Styria GmbH, page 11Life Science Austria (LISA) Vienna Region, page 12OÖ. Technologie- und Marketinggesellschaft m.b.H., page 13Technopol Krems, page 14Technopol Tulln, page 14Tiroler Zukunftsstiftung, page 15

ADVERTISERS

SUPPLIERS

BIOPROCESSING

RESEARCH AND DEVELOPMENT

DIAGNOSTICS

PHARMACEUTICALS

Z

V

U

T

S

R

Q


AUSTRIAEXPORT > INDEXAUSTRIAEXPORT > INDEXAUSTRIAEXPORT > AUSTRIAN TRADE OFFICES ABROAD

ALGERIA17, Chemin Abdelkader GaddoucheDZ-16035 Hydra – Alger/AlgérieT. +213/21/69 12 29, 69 27 54F. +213/21/69 15 [email protected]/dz

ARGENTINACerrito 1294, piso 15°C 1010 AAZ Buenos Aires/ArgentinaT. +54/11/48 16 04 79F. +54/11/48 14 36 [email protected]/ar

AUSTRALIA10th floor, 1, York StreetSydney NSW 2000/AustraliaT. +61/2/92 47 85 81F. +61/2/92 51 10 [email protected]/au

BELGIUM479, Avenue Louise, Boîte 52B-1050 Bruxelles/BelgiqueT. +32/2/645 16 50F. +32/2/645 16 [email protected]/be

BOSNIA-HERZEGOVINAFra Andjela Zvizdovica 1/19, Tower BBiH-71000 Sarajevo/Bosnia-HerzegovinaT. +387/33/26 78 40, 26 78 50F. +387/33/22 23 [email protected]/ba

BRAZIL Edificio Network EmpresarialAv. Dr. Cardoso de Melo, 1340 – conj. 71BR-04548-004 São Paulo – SP/BrazilT. +55/11/30 44 99 44F. +55/11/38 42 53 [email protected]/br

BULGARIAul. Samuil 35BG-1000 Sofia/BulgariaT. +359/2/953 15 53F. +359/2/953 24 26isdn +359/2/950 21 [email protected]/bg

CANADA2 Bloor Street West, Suite 400Toronto, ON M4W 3E2/CanadaT. +1/416/967 3348, 967 3380F. +1/416/967 [email protected]/ca

1010 ouest, rue Sherbrooke, Suite 1410Montréal, QC H3A 2R7/CanadaT. +1/514/849 3708F. +1/514/849 [email protected]/ca

CHILEIsidora Goyenechea 2934,Of. 601, Las CondesSantiago/ChileT. +56/2/233 05 57F. +56/2/233 69 [email protected]/cl

CHINA Suite 2280 Beijing Sunflower TowerNo. 37 Maizidian Street Chaoyang District Beijing 100026/The People’s Republic ofChinaT. +86/10/85 27 50 50F. +86/10/85 27 50 [email protected]/cn

Suite 514, West TowerShanghai Centre, P.O.Box 1551376 Nanjing Xi LuShanghai 200040/The People’s Republic ofChinaT. +86/21/62 79 71 97F. +86/21/62 79 71 [email protected]/cn

13/F, Diamond Exchange Building8-10 Duddell Street, CentralHongkong/The People’s Republic of ChinaT. +852/25 22 23 88F. +852/28 10 64 [email protected]/cn

CROATIAIlica 12/2. St.HR-10000 Zagreb/CroatiaT. +385/1/488 19 00F. +385/1/488 19 [email protected]/hr

CZECH REPUBLICKrakovská 7CZ-111 21 Praha 1/Czech RepublicT. +420/222 21 02 55F. +420/222 21 12 [email protected]/cz

DENMARKGrønningen 5, IIIDK-1270 København K./DanmarkT. +45/33 11 14 12F. +45/33 91 14 [email protected]/dk

EGYPT8, Ismail Mohamed Street - ZamalekCairo/Arab Republic of EgyptT. +20/2/735 76 07, 736 11 50, 736 55 63,736 95 09, 735 17 25F. +20/2/736 28 [email protected]/eg

EUROPEAN UNIONAvenue de Cortenbergh 30B-1040 Bruxelles/BelgiqueT. +32/2/286 58 80F. +32/2/286 58 [email protected]

FINLANDMannerheimintie 15aBFIN-00260 Helsinki/FinlandT. +358/9/436 63 30F. +358/9/43 66 33 [email protected]/fi

FRANCE6, avenue Pierre 1er de SerbieF-75116 Paris/FranceT. +33/1/53 23 05 05F. +33/1/47 20 64 [email protected]/fr

14, quai KléberF-67000 Strasbourg/FranceT. +33/3/88 52 29 60F. +33/3/88 52 29 [email protected]/fr

GERMANYStauffenbergstraße 1D-10785 Berlin/GermanyT. +49/30/25 75 75 0F. +49/30/25 75 75 [email protected]/de

Unterlindau 21-29D-60323 Frankfurt am Main/GermanyT. +49/69/97 10 12-0F. +49/69/97 10 [email protected]/de

Promenadeplatz 12/5D-80333 München/GermanyT. +49/89/24 29 14-0F. +49/89/24 29 [email protected]/de

GREECETritis Septemvriou 43 AGR-104 33 Athen/GreeceT. +30/210/884 37 11F. +30/210/882 79 [email protected]/gr

HUNGARY Délibáb utca 21H-1062 Budapest VI/HungaryT. +36/1/461 50 40F. +36/1/351 12 [email protected]/hu

INDIA85, Jor BaghNew Delhi 110 003/IndiaT. +91/11/24 61 83 95, 24 61 83 97, 24 69 17 80-82F. +91/11/24 61 87 [email protected]/in

INDONESIAMenara Kadin Indonesia, 19th FloorJalan H. R. Rasuna Said Blok X-5, Kav. 2&3Jakarta 12950/IndonesiaT. +62/21/25 50 01 86F. +62/21/527 47 [email protected]/id

IRAQ Hay Babil 929Street No. 30, House No. 38MasbahBaghdad/Iraqsat-T. +87 37 61 35 38 67 sat-F. +87 37 61 35 38 [email protected]/iq

IRANAfrica ExpresswayGolgasht Street 21Teheran/IranT. +98/21/2205 18 20, 2204 77 91, 2201 66 28F. +98/21/2205 18 [email protected]/ir

IRELANDMerrion CentreNutley LaneDublin 4/IrelandT. +353/1/283 04 88F. +353/1/283 05 [email protected]/ie

ISRAELTrade Tower, 9th Floor25, Hamered StreetTel Aviv/IsraelT. +972/3/516 86 85F. +972/3/516 85 [email protected]/il

ITALYPiazza del Duomo 20I-20122 Milano/ItaliaT. +39/02/879 09 11F. +39/02/87 73 [email protected]/it

Via E. Filiberto, 3I-35122 Padova/ItaliaT. +39/049/876 25 30,876 26 98, 876 27 21T. +39/049/876 27 [email protected]/it

JAPAN13-3, 3-Chome, Motoazabu Minato-ku,Tokyo 106-0046/JapanT. +81/3/34 03 17 77F. +81/3/34 03 34 [email protected]/jp

KOREA Kyobo Building, Room 19141-1, Jongno, 1-ga, Jongno-guSeoul 110-714 /Republic of KoreaT. +82/2/732 73 30, 732 66 49F. +82/2/732 43 [email protected]/kr

LIBYA 11-13 Shara el AmirAbdulkader el JazairiTripoli/LibyaT. +218/21/333 51 76, 333 51 77, 333 04 16F. +218/21/333 73 [email protected]/ly

MALAYSIASuite 14.1, Level 14, Menara IMCNo. 8, Jalan Sultan Ismail50250 Kuala Lumpur/MalaysiaT. +60/3/20 32 28 30F. +60/3/20 32 31 [email protected]/my

MOROCCO45, Avenue Hassan II20000 Casablanca/MarocT. +212/22/22 32 82, 22 47 70, 26 69 04F. +212/22/22 10 [email protected]/ma


AUSTRIAEXPORT > INDEXAUSTRIAEXPORT > INDEXAUSTRIAEXPORT > AUSTRIAN TRADE OFFICES ABROAD

MEXICOAvenida Presidente Masaryk 101, 9. StockCol. Chapultepec Morales (Polanco)Delegación Miguel Hidalgo11570 México, D.F./MéxicoT. +52/55 52 54 44 18,55 52 54 44 28, 55 52 54 44 38F. +52/55 52 55 16 [email protected]/mx

NETHERLANDSLange Voorhout 58 a2514 EG Den Haag/NederlandT. +31/70/365 49 16F. +31/70/365 73 [email protected]/nl

NIGERIA 65A, Oyinkan Abayomi Drive, IkoyiLagos/NigeriaT. +234/1/461 35 86, 461 35 87,269 62 13, 269 04 23, 267 19 55F. +234/1/461 35 [email protected]/ng

NORWAYOscars gate 81N-0256 Oslo/NorgeT. +47/24 11 78 00F. +47/24 11 78 [email protected]/no

PHILIPPINES14th Floor, The Pacific Star Bldg.Sen. Gil J. Puyat Ave./Corner Makati Ave.1200 Makati City, Metro Manila/PhilippinesT. +63/2/818 15 81F. +63/2/810 37 [email protected]/ph

POLAND Saski Cresent Center, ul. Królewska 16,PL-00-103 Warszawa/PolandT. +48/22/586 44 66F. +48/22/586 44 [email protected]/pl

PORTUGALRua Rodrigues Sampaio, 18-5°P-1169-027 Lisboa/PortugalT. +351/213 17 10 10F. +351/213 17 10 [email protected]/pt

ROMANIAStrada Logofat Luca Stroici Nr. 15RO-020581 Bucuresti/RomaniaT. +40/21/210 17 98, 210 17 99F. +40/21/210 23 [email protected]/ro

RUSSIAStarokonjuschennyi per. 1119 034 Moskau/RussiaT. +7/495/725 63 66F. +7/495/230 26 [email protected]/ru

SAUDI ARABIANew Jeddah Chamber of Commerce & Industry BuildingAl-RuwaisJeddah 21441/Saudi ArabiaT. +966/2/651 18 16, 651 23 04F. +966/2/653 37 [email protected]/sa

Kingdom Tower 23rd FloorOlaya District, Arouba RoadRiyadh 11693/Saudi ArabiaT. +966/1/211 01 11, 211 01 71, 211 01 77F. +966/1/211 02 [email protected]/sa

SERBIA AND MONTENEGROGenex Apartmani, Apt. 103Vladimira Popovica 6CS-11070 Novi Beograd/Srbija i Crna GoraT. +381/11/301 58 50F. +381/11/311 21 [email protected]/cs

SINGAPORE600 North Bridge Road#24-04/05 Parkview SquareSingapore 188778/Rep. of SingaporeT. +65/63 96 63 50, 63 96 63 51, 63 96 63 52F. +65/63 96 63 [email protected]/sg

SLOVAKIAEuropeum Business CentreSuché my’to 1, Stiege A, 3. StockSK-811 03 Bratislava/SlovenskoT. +421/2/59 100 600F. +421/2/59 100 [email protected]/sk

SLOVENIANazorjeva 6Postni predal 1595SI-1000 Ljubljana/SlovenijaT. +386/1/513 97 70F. +386/1/513 97 [email protected]/si

SOUTH AFRICACradock Heights, 2nd Floor21 Cradock Avenue (Corner Tyrwhitt Avenue)Rosebank (Johannesburg)/Rep. of SouthAfricaT. +27/11/442 71 00F. +27/11/442 83 [email protected]/za

SPAINOrense, 11-6°E-28020 Madrid/EspañaT. +34/91 556 43 58F. +34/91 556 99 [email protected]/es

Balmes, 200-7°/1 aE-08006 Barcelona/EspañaT. +34/93 292 23 78F. +34/93 237 76 [email protected]/es

SWEDENKarlaplan 12SE-11520 Stockholm/SchwedenT. +46/8/53 48 88 40F. +46/8/660 83 [email protected]/se

SWITZERLANDTalstraße 65, 10 OGCH-8001 Zürich/SwitzerlandT. +41/44/215 30 40F. +41/44/212 28 [email protected]/ch

SYRIAMezzeh, Eastern VillasFarabi Street 116aDamascus/SyriaT. +963/11/611 77 71, 611 46 16F. +963/11/613 20 [email protected]/sy

TAIWANBank Tower, Suite 608 Dunhua N. Rd. 205Taipei 105/TaiwanT. +886/2/27 15 52 20F. +886/2/27 17 32 [email protected]/tw

THAILAND Chartered Square Building, 14th Floor, Suite 1403152 North Sathorn RoadBangkok 10500/ThailandT. +66/2/268 22 22F. +66/2/200 02 [email protected]/th

TURKEY Armada Business CenterEskisehir Yolu 6, Floor 13, Office 1906520 SögütözüAnkara, TurkeyT. +90/312/219 21 41 (PBX)F. +90/312/219 21 [email protected]/tr

Avusturya Dıs, Ticaret OfisiBüyükdere Caddesi 100-102Maya Akar Center B Blok, Floor 14, Office51TR-34394 Esentepe – Istanbul/TurkeyT. +90/212/211 14 76F. +90/212/212 01 [email protected]/tr

UKRAINEwul. Volodimirska, 48 A, 2. Stock01034 Kiew/UkraineT. +380/44/235 13 41, 235 03 18F. +380/44/230 25 [email protected]/ua

UNITED ARAB EMIRATES Al Khazna Tower, 7th FloorAl Najda StreetAbu Dhabi/United Arab EmiratesT. +971/2/676 66 33F. +971/2/676 00 [email protected]/ae

UNITED KINGDOM45, Princes Gate (Exhibition Road)London SW7 2QA/United KingdomT. +44/20/75 84 44 11F. +44/20/75 84 25 [email protected]/uk

USA120 West 45th Street, 9th FloorNew York, NY 10036/USAT. +1/212/421-5250F. +1/212/[email protected]/us

500 North Michigan Avenue, Suite 1950Chicago, IL 60611-3722/USAT. +1/312/644-5556F. +1/312/[email protected]/us

11601 Wilshire Blvd., Suite 2420Los Angeles, CA 90025/USAT. +1/310/477-9988F. +1/310/[email protected]/us

VENEZUELAEdificio Plaza C/PHCalle Londres entre Caroni y Nueva YorkLas MercedesCaracas/VenezuelaT. +58/212/993 98 44F. +58/212/993 99 [email protected]/ve

CPG I Corporate Publishing Group, Strozzigasse 10/EG, A-1080 Wien I Tel.: + 43 1 4054640-763 I E-Mail: [email protected]

Harte Zeiten brauchen neue Ideen: Die CPG verleiht Ihrem Umsatz

mit maßgeschneiderter Kommunikation Flügel. Mit Magazinen,

Magalogen, Zeitschriften und Broschüren, die Mitarbeiter motivieren,

Endverbraucher informieren und Geschäftspartner von Ihnen und

Ihren Produkten überzeugen. Weltweit, mit den besten Partnern vor Ort.

CPG – Ihr Partner von Welt.

Referenzen I Abbott Diagnostica I Außenwirtschaft/Wirtschaftskammer Österreich IBiotherm I Capital Bank I Designbau I Golfclub Leopoldsdorf I Inode I M&A PrivatBank I Nestlé INovomatic I ÖSW I Peugeot I Post & Telekom Immobilien I Schwabe, Ley & Greiner I Seat IUTA I zBp I ZEPRA … und wann entscheiden Sie sich für die CPG?

IHR OUTSOURCING-PARTNER

CPG

mailto:[email protected]

AUSTRIAEXPORT - Advantage Austria · 60 million euros annually for R&D in Austria. The latest...

Documents

Transcript of AUSTRIAEXPORT - Advantage Austria · 60 million euros annually for R&D in Austria. The latest...